TW200901987A - Triazole derivatives which are Smo antagonists - Google Patents
Triazole derivatives which are Smo antagonists Download PDFInfo
- Publication number
- TW200901987A TW200901987A TW097113665A TW97113665A TW200901987A TW 200901987 A TW200901987 A TW 200901987A TW 097113665 A TW097113665 A TW 097113665A TW 97113665 A TW97113665 A TW 97113665A TW 200901987 A TW200901987 A TW 200901987A
- Authority
- TW
- Taiwan
- Prior art keywords
- cancer
- compound
- phenyl
- methyl
- bicyclo
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title description 12
- 229940042055 systemic antimycotics triazole derivative Drugs 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 116
- 150000003839 salts Chemical class 0.000 claims abstract description 46
- 238000011282 treatment Methods 0.000 claims abstract description 36
- 239000012453 solvate Substances 0.000 claims abstract description 18
- 230000002265 prevention Effects 0.000 claims abstract description 15
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 14
- 230000008485 antagonism Effects 0.000 claims abstract description 12
- 229910052731 fluorine Chemical group 0.000 claims abstract description 11
- 125000004429 atom Chemical group 0.000 claims abstract description 8
- 239000001257 hydrogen Substances 0.000 claims abstract description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 7
- 230000001668 ameliorated effect Effects 0.000 claims abstract description 6
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims abstract description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 75
- 210000004027 cell Anatomy 0.000 claims description 47
- 201000011510 cancer Diseases 0.000 claims description 41
- 239000003814 drug Substances 0.000 claims description 39
- -1 fluoro-1-methylethyl Chemical group 0.000 claims description 27
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims description 18
- ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical group [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 239000002246 antineoplastic agent Substances 0.000 claims description 13
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 11
- 206010025323 Lymphomas Diseases 0.000 claims description 11
- 206010039491 Sarcoma Diseases 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 9
- VEUMBMHMMCOFAG-UHFFFAOYSA-N 2,3-dihydrooxadiazole Chemical compound N1NC=CO1 VEUMBMHMMCOFAG-UHFFFAOYSA-N 0.000 claims description 7
- 208000032612 Glial tumor Diseases 0.000 claims description 7
- 206010018338 Glioma Diseases 0.000 claims description 7
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 201000009030 Carcinoma Diseases 0.000 claims description 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 206010027191 meningioma Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 claims description 3
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 claims description 3
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 239000002534 radiation-sensitizing agent Substances 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 1
- SNTWKPAKVQFCCF-UHFFFAOYSA-N 2,3-dihydro-1h-triazole Chemical compound N1NC=CN1 SNTWKPAKVQFCCF-UHFFFAOYSA-N 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 230000002380 cytological effect Effects 0.000 claims 1
- 125000006001 difluoroethyl group Chemical group 0.000 claims 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- XVQUOJBERHHONY-UHFFFAOYSA-N isometheptene Chemical compound CNC(C)CCC=C(C)C XVQUOJBERHHONY-UHFFFAOYSA-N 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 claims 1
- 238000005096 rolling process Methods 0.000 claims 1
- 239000002023 wood Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 39
- 238000000034 method Methods 0.000 abstract description 27
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 32
- 239000000243 solution Substances 0.000 description 25
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 239000003795 chemical substances by application Substances 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 201000010099 disease Diseases 0.000 description 21
- 239000002904 solvent Substances 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 229910001868 water Inorganic materials 0.000 description 19
- 235000019439 ethyl acetate Nutrition 0.000 description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 17
- 239000000047 product Substances 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 230000037361 pathway Effects 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 239000003112 inhibitor Substances 0.000 description 13
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 208000009956 adenocarcinoma Diseases 0.000 description 11
- 201000000053 blastoma Diseases 0.000 description 11
- 201000008184 embryoma Diseases 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 10
- 101150041968 CDC13 gene Proteins 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 9
- 238000005481 NMR spectroscopy Methods 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000012894 fetal calf serum Substances 0.000 description 9
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 9
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- 210000000276 neural tube Anatomy 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 206010041823 squamous cell carcinoma Diseases 0.000 description 8
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 8
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 7
- 244000060234 Gmelina philippensis Species 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 7
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 7
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000001959 radiotherapy Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 206010041067 Small cell lung cancer Diseases 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 235000003599 food sweetener Nutrition 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 6
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 5
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 5
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 102000003693 Hedgehog Proteins Human genes 0.000 description 5
- 108090000031 Hedgehog Proteins Proteins 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- 201000004681 Psoriasis Diseases 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000004020 luminiscence type Methods 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 235000008160 pyridoxine Nutrition 0.000 description 5
- 239000011677 pyridoxine Substances 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 208000000587 small cell lung carcinoma Diseases 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229960005322 streptomycin Drugs 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 229940011671 vitamin b6 Drugs 0.000 description 5
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 4
- 108010092160 Dactinomycin Proteins 0.000 description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 4
- 108010069236 Goserelin Proteins 0.000 description 4
- 208000018142 Leiomyosarcoma Diseases 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 102100021796 Sonic hedgehog protein Human genes 0.000 description 4
- 206010043276 Teratoma Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 229960000975 daunorubicin Drugs 0.000 description 4
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 4
- 229960002989 glutamic acid Drugs 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 201000011066 hemangioma Diseases 0.000 description 4
- 201000010260 leiomyoma Diseases 0.000 description 4
- 239000004530 micro-emulsion Substances 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 208000024794 sputum Diseases 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 229960003087 tioguanine Drugs 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 3
- GETTZEONDQJALK-UHFFFAOYSA-N (trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1 GETTZEONDQJALK-UHFFFAOYSA-N 0.000 description 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 3
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 3
- FEJUGLKDZJDVFY-UHFFFAOYSA-N 9-borabicyclo[3.3.1]nonane Substances C1CCC2CCCC1B2 FEJUGLKDZJDVFY-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 108010006654 Bleomycin Proteins 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 201000005262 Chondroma Diseases 0.000 description 3
- 230000004568 DNA-binding Effects 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 201000008808 Fibrosarcoma Diseases 0.000 description 3
- 108010029961 Filgrastim Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108010047761 Interferon-alpha Proteins 0.000 description 3
- 102000006992 Interferon-alpha Human genes 0.000 description 3
- 208000007766 Kaposi sarcoma Diseases 0.000 description 3
- 206010024612 Lipoma Diseases 0.000 description 3
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 3
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 3
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 235000019483 Peanut oil Nutrition 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 206010046798 Uterine leiomyoma Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 description 3
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- 229940045799 anthracyclines and related substance Drugs 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229960005243 carmustine Drugs 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960002436 cladribine Drugs 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 229960000640 dactinomycin Drugs 0.000 description 3
- NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 3
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 229960001691 leucovorin Drugs 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 3
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 239000000312 peanut oil Substances 0.000 description 3
- 108010027841 pegademase bovine Proteins 0.000 description 3
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000004853 protein function Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 3
- 229960004641 rituximab Drugs 0.000 description 3
- 108010038379 sargramostim Proteins 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229960001603 tamoxifen Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 229960005267 tositumomab Drugs 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 2
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- PMWGIVRHUIAIII-UHFFFAOYSA-N 2,2-difluoropropanoic acid Chemical compound CC(F)(F)C(O)=O PMWGIVRHUIAIII-UHFFFAOYSA-N 0.000 description 2
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 2
- WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 2
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- 206010007275 Carcinoid tumour Diseases 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 206010011017 Corneal graft rejection Diseases 0.000 description 2
- 108010019673 Darbepoetin alfa Proteins 0.000 description 2
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 2
- 206010058314 Dysplasia Diseases 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 241000237858 Gastropoda Species 0.000 description 2
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241001272567 Hominoidea Species 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 2
- 241000254158 Lampyridae Species 0.000 description 2
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 2
- 229930192392 Mitomycin Natural products 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- SHGAZHPCJJPHSC-UHFFFAOYSA-N Panrexin Chemical compound OC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-UHFFFAOYSA-N 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229940064305 adrucil Drugs 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000002111 antiemetic agent Substances 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003886 aromatase inhibitor Substances 0.000 description 2
- 229940046844 aromatase inhibitors Drugs 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 2
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
- 229960002092 busulfan Drugs 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 229910000420 cerium oxide Inorganic materials 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 229960003901 dacarbazine Drugs 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 108010017271 denileukin diftitox Proteins 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960000605 dexrazoxane Drugs 0.000 description 2
- 229940115080 doxil Drugs 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 229960001904 epirubicin Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 239000002834 estrogen receptor modulator Substances 0.000 description 2
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 229960004177 filgrastim Drugs 0.000 description 2
- 229960000961 floxuridine Drugs 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 235000008191 folinic acid Nutrition 0.000 description 2
- 239000011672 folinic acid Substances 0.000 description 2
- 229960002258 fulvestrant Drugs 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 229960003690 goserelin acetate Drugs 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
- 229960002247 lomustine Drugs 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 229960004961 mechlorethamine Drugs 0.000 description 2
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 229960000901 mepacrine Drugs 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229940101533 mesnex Drugs 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 229940090009 myleran Drugs 0.000 description 2
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 2
- UBWXUGDQUBIEIZ-QNTYDACNSA-N nandrolone phenpropionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@H]4CCC(=O)C=C4CC3)CC[C@@]21C)C(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-QNTYDACNSA-N 0.000 description 2
- 208000004235 neutropenia Diseases 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 229940127084 other anti-cancer agent Drugs 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 2
- 229960001218 pegademase Drugs 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 229960000952 pipobroman Drugs 0.000 description 2
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 2
- 229960003171 plicamycin Drugs 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229940117820 purinethol Drugs 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000002181 pyridoxine group Chemical group 0.000 description 2
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 229910052707 ruthenium Inorganic materials 0.000 description 2
- 150000003304 ruthenium compounds Chemical class 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 229960003440 semustine Drugs 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 230000007958 sleep Effects 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229940099419 targretin Drugs 0.000 description 2
- 229940063683 taxotere Drugs 0.000 description 2
- 229960005353 testolactone Drugs 0.000 description 2
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 229960001055 uracil mustard Drugs 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- HHJUWIANJFBDHT-KOTLKJBCSA-N vindesine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(N)=O)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 HHJUWIANJFBDHT-KOTLKJBCSA-N 0.000 description 2
- 229960004355 vindesine Drugs 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- 229940033942 zoladex Drugs 0.000 description 2
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- XGQXULJHBWKUJY-LYIKAWCPSA-N (z)-but-2-enedioic acid;n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide Chemical compound OC(=O)\C=C/C(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C XGQXULJHBWKUJY-LYIKAWCPSA-N 0.000 description 1
- 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 description 1
- VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- TXQPXJKRNHJWAX-UHFFFAOYSA-N 2-(3-aminopropylamino)ethylsulfanylphosphonic acid;trihydrate Chemical compound O.O.O.NCCCNCCSP(O)(O)=O TXQPXJKRNHJWAX-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- NZDOWZQRNZLBOY-UHFFFAOYSA-N 2-fluoro-2-methylpropanoic acid Chemical compound CC(C)(F)C(O)=O NZDOWZQRNZLBOY-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- JVYNJRBSXBYXQB-UHFFFAOYSA-N 4-[3-(4-carboxyphenoxy)propoxy]benzoic acid;decanedioic acid Chemical compound OC(=O)CCCCCCCCC(O)=O.C1=CC(C(=O)O)=CC=C1OCCCOC1=CC=C(C(O)=O)C=C1 JVYNJRBSXBYXQB-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- KBZVAQVEHVGIEI-UHFFFAOYSA-N 4-methoxycarbonylbicyclo[2.2.2]octane-1-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(C(=O)OC)CC2 KBZVAQVEHVGIEI-UHFFFAOYSA-N 0.000 description 1
- 229940113081 5 Hydroxytryptamine 3 receptor antagonist Drugs 0.000 description 1
- 102000035037 5-HT3 receptors Human genes 0.000 description 1
- 108091005477 5-HT3 receptors Proteins 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- AMKGKYQBASDDJB-UHFFFAOYSA-N 9$l^{2}-borabicyclo[3.3.1]nonane Chemical compound C1CCC2CCCC1[B]2 AMKGKYQBASDDJB-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 206010001257 Adenoviral conjunctivitis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N Arsenious Acid Chemical compound O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- 206010062804 Basal cell naevus syndrome Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 206010004950 Birth mark Diseases 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 206010073106 Bone giant cell tumour malignant Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 206010006417 Bronchial carcinoma Diseases 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- ZHCCQKNKIMBSRW-UHFFFAOYSA-N CC(F)(S)C(O)=O Chemical compound CC(F)(S)C(O)=O ZHCCQKNKIMBSRW-UHFFFAOYSA-N 0.000 description 1
- 101100451537 Caenorhabditis elegans hsd-1 gene Proteins 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000009043 Chemical Burns Diseases 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- MPONAPFARZGDTH-UHFFFAOYSA-N Cl.OS(O)=O Chemical compound Cl.OS(O)=O MPONAPFARZGDTH-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- HVXBOLULGPECHP-WAYWQWQTSA-N Combretastatin A4 Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000025133 Congenital eye disease Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 101150073133 Cpt1a gene Proteins 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102100021906 Cyclin-O Human genes 0.000 description 1
- QASFUMOKHFSJGL-LAFRSMQTSA-N Cyclopamine Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H](CC2=C3C)[C@@H]1[C@@H]2CC[C@@]13O[C@@H]2C[C@H](C)CN[C@H]2[C@H]1C QASFUMOKHFSJGL-LAFRSMQTSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000007659 Fibroadenoma Diseases 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000007569 Giant Cell Tumors Diseases 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 208000031995 Gorlin syndrome Diseases 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000002927 Hamartoma Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 206010019629 Hepatic adenoma Diseases 0.000 description 1
- 208000031953 Hereditary hemorrhagic telangiectasia Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 241000282596 Hylobatidae Species 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102100039064 Interleukin-3 Human genes 0.000 description 1
- CLEXYFLHGFJONT-DNMILWOZSA-N Jervine Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H](C(=O)C2=C3C)[C@@H]1[C@@H]2CC[C@@]13O[C@@H]2C[C@H](C)CN[C@H]2[C@H]1C CLEXYFLHGFJONT-DNMILWOZSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 208000002404 Liver Cell Adenoma Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 206010062207 Mycobacterial infection Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 206010031149 Osteitis Diseases 0.000 description 1
- 208000000035 Osteochondroma Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 201000002154 Pterygium Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 108010052090 Renilla Luciferases Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 208000005678 Rhabdomyoma Diseases 0.000 description 1
- 229910006124 SOCl2 Inorganic materials 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 1
- UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
- 241001061127 Thione Species 0.000 description 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 244000126014 Valeriana officinalis Species 0.000 description 1
- 235000013832 Valeriana officinalis Nutrition 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 208000010011 Vitamin A Deficiency Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 206010048214 Xanthoma Diseases 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- PCWZKQSKUXXDDJ-UHFFFAOYSA-N Xanthotoxin Natural products COCc1c2OC(=O)C=Cc2cc3ccoc13 PCWZKQSKUXXDDJ-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- MBHRHUJRKGNOKX-UHFFFAOYSA-N [(4,6-diamino-1,3,5-triazin-2-yl)amino]methanol Chemical compound NC1=NC(N)=NC(NCO)=N1 MBHRHUJRKGNOKX-UHFFFAOYSA-N 0.000 description 1
- KSPMJHKUXSQDSZ-UHFFFAOYSA-N [N].[N] Chemical compound [N].[N] KSPMJHKUXSQDSZ-UHFFFAOYSA-N 0.000 description 1
- XAQHXGSHRMHVMU-UHFFFAOYSA-N [S].[S] Chemical compound [S].[S] XAQHXGSHRMHVMU-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 229940028652 abraxane Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940060205 adagen Drugs 0.000 description 1
- 208000002718 adenomatoid tumor Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940110282 alimta Drugs 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229940098174 alkeran Drugs 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229960001097 amifostine Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002973 anti-dopamine Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000002682 anti-psoriatic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 1
- 229940115115 aranesp Drugs 0.000 description 1
- 229940078010 arimidex Drugs 0.000 description 1
- 229940087620 aromasin Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 239000012911 assay medium Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000012115 autosomal dominant keratitis Diseases 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 229940108502 bicnu Drugs 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 208000018339 bone inflammation disease Diseases 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 201000002143 bronchus adenoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940112133 busulfex Drugs 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
- 229960002882 calcipotriol Drugs 0.000 description 1
- IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
- 229950009823 calusterone Drugs 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- 229940088954 camptosar Drugs 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229940047495 celebrex Drugs 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 230000012820 cell cycle checkpoint Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 208000013557 cerebral hemisphere cancer Diseases 0.000 description 1
- 201000008860 cerebrum cancer Diseases 0.000 description 1
- DRVWBEJJZZTIGJ-UHFFFAOYSA-N cerium(3+);oxygen(2-) Chemical class [O-2].[O-2].[O-2].[Ce+3].[Ce+3] DRVWBEJJZZTIGJ-UHFFFAOYSA-N 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 1
- 229960004588 cilostazol Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 229960000928 clofarabine Drugs 0.000 description 1
- 229940103380 clolar Drugs 0.000 description 1
- 238000010549 co-Evaporation Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229960005537 combretastatin A-4 Drugs 0.000 description 1
- HVXBOLULGPECHP-UHFFFAOYSA-N combretastatin A4 Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-UHFFFAOYSA-N 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 108010084052 continuous erythropoietin receptor activator Proteins 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229940088547 cosmegen Drugs 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 1
- QASFUMOKHFSJGL-UHFFFAOYSA-N cyclopamine Natural products C1C=C2CC(O)CCC2(C)C(CC2=C3C)C1C2CCC13OC2CC(C)CNC2C1C QASFUMOKHFSJGL-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229940094488 cytarabine liposome Drugs 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Natural products NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960005029 darbepoetin alfa Drugs 0.000 description 1
- 229940026692 decadron Drugs 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 229960002923 denileukin diftitox Drugs 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 229940070968 depocyt Drugs 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- HQWPLXHWEZZGKY-UHFFFAOYSA-N diethylzinc Chemical compound CC[Zn]CC HQWPLXHWEZZGKY-UHFFFAOYSA-N 0.000 description 1
- JDZLOJYSBBLXQD-UHFFFAOYSA-N difluoromethylbenzene Chemical compound FC(F)C1=CC=CC=C1 JDZLOJYSBBLXQD-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- NYDXNILOWQXUOF-UHFFFAOYSA-L disodium;2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate Chemical compound [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)NC(CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000002804 dopamine agent Substances 0.000 description 1
- 229940017825 dromostanolone Drugs 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 229950004683 drostanolone propionate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229960000284 efalizumab Drugs 0.000 description 1
- 229940053603 elitek Drugs 0.000 description 1
- 229940087477 ellence Drugs 0.000 description 1
- 229940120655 eloxatin Drugs 0.000 description 1
- 229940073038 elspar Drugs 0.000 description 1
- 201000002246 embryonal cancer Diseases 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 229940000733 emcyt Drugs 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 208000021373 epidemic keratoconjunctivitis Diseases 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical group OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940043168 fareston Drugs 0.000 description 1
- 229940087861 faslodex Drugs 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229940087476 femara Drugs 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- XSFJVAJPIHIPKU-XWCQMRHXSA-N flunisolide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O XSFJVAJPIHIPKU-XWCQMRHXSA-N 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229960000936 fumagillin Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 229940020967 gemzar Drugs 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 229940084910 gliadel Drugs 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
- 229960003727 granisetron Drugs 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 201000002735 hepatocellular adenoma Diseases 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 229940003183 hexalen Drugs 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- BKEMVGVBBDMHKL-VYFXDUNUSA-N histrelin acetate Chemical compound CC(O)=O.CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 BKEMVGVBBDMHKL-VYFXDUNUSA-N 0.000 description 1
- 229960003911 histrelin acetate Drugs 0.000 description 1
- 239000004030 hiv protease inhibitor Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229940088013 hycamtin Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229940096120 hydrea Drugs 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 229940099279 idamycin Drugs 0.000 description 1
- 229940090411 ifex Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- 229940124622 immune-modulator drug Drugs 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- CLEXYFLHGFJONT-UHFFFAOYSA-N jervine Natural products C1C=C2CC(O)CCC2(C)C(C(=O)C2=C3C)C1C2CCC13OC2CC(C)CNC2C1C CLEXYFLHGFJONT-UHFFFAOYSA-N 0.000 description 1
- QRXOCOSLDOPPKH-UHFFFAOYSA-N jervine sulfate Natural products CC1CNC2C(C1)OC3(CCC4=C(C3C)C(=O)C5C4CC=C6CC(O)CCC56C)C2C QRXOCOSLDOPPKH-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940063199 kenalog Drugs 0.000 description 1
- 229940065223 kepivance Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- 229940063725 leukeran Drugs 0.000 description 1
- 229940087875 leukine Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 108010078259 luprolide acetate gel depot Proteins 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 229940100029 lysodren Drugs 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 201000004593 malignant giant cell tumor Diseases 0.000 description 1
- 201000000289 malignant teratoma Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 229940087732 matulane Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940090004 megace Drugs 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- SLVMESMUVMCQIY-UHFFFAOYSA-N mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 description 1
- 229960000300 mesoridazine Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229960004469 methoxsalen Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- OIRDBPQYVWXNSJ-UHFFFAOYSA-N methyl trifluoromethansulfonate Chemical compound COS(=O)(=O)C(F)(F)F OIRDBPQYVWXNSJ-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 231100000782 microtubule inhibitor Toxicity 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 229940087004 mustargen Drugs 0.000 description 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 208000009091 myxoma Diseases 0.000 description 1
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 229960001133 nandrolone phenpropionate Drugs 0.000 description 1
- 229940086322 navelbine Drugs 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229940071846 neulasta Drugs 0.000 description 1
- 229940082926 neumega Drugs 0.000 description 1
- 229940029345 neupogen Drugs 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 239000002742 neurokinin 1 receptor antagonist Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 201000005734 nevoid basal cell carcinoma syndrome Diseases 0.000 description 1
- 229940080607 nexavar Drugs 0.000 description 1
- 229940109551 nipent Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- 229940085033 nolvadex Drugs 0.000 description 1
- 239000003956 nonsteroidal anti androgen Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 229940100027 ontak Drugs 0.000 description 1
- 108010046821 oprelvekin Proteins 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 208000003388 osteoid osteoma Diseases 0.000 description 1
- 229940045681 other alkylating agent in atc Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- BMMGVYCKOGBVEV-UHFFFAOYSA-N oxo(oxoceriooxy)cerium Chemical compound [Ce]=O.O=[Ce]=O BMMGVYCKOGBVEV-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229950007318 ozogamicin Drugs 0.000 description 1
- 229960002404 palifermin Drugs 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- 229940096763 panretin Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940048111 pegademase bovine Drugs 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 108010001564 pegaspargase Proteins 0.000 description 1
- 108010044644 pegfilgrastim Proteins 0.000 description 1
- 229960003349 pemetrexed disodium Drugs 0.000 description 1
- NYDXNILOWQXUOF-GXKRWWSZSA-L pemetrexed disodium Chemical compound [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-GXKRWWSZSA-L 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 229940067157 phenylhydrazine Drugs 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229940109328 photofrin Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 229940063179 platinol Drugs 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229940098901 polifeprosan 20 Drugs 0.000 description 1
- 229960004293 porfimer sodium Drugs 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 208000028172 protozoa infectious disease Diseases 0.000 description 1
- FYBHCRQFSFYWPY-UHFFFAOYSA-N purmorphamine Chemical compound C1CCCCC1N1C2=NC(OC=3C4=CC=CC=C4C=CC=3)=NC(NC=3C=CC(=CC=3)N3CCOCC3)=C2N=C1 FYBHCRQFSFYWPY-UHFFFAOYSA-N 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 108010084837 rasburicase Proteins 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 102000027483 retinoid hormone receptors Human genes 0.000 description 1
- 108091008679 retinoid hormone receptors Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- HNMATTJJEPZZMM-BPKVFSPJSA-N s-[(2r,3s,4s,6s)-6-[[(2r,3s,4s,5r,6r)-5-[(2s,4s,5s)-5-[acetyl(ethyl)amino]-4-methoxyoxan-2-yl]oxy-6-[[(2s,5z,9r,13e)-13-[2-[[4-[(2e)-2-[1-[4-(4-amino-4-oxobutoxy)phenyl]ethylidene]hydrazinyl]-2-methyl-4-oxobutan-2-yl]disulfanyl]ethylidene]-9-hydroxy-12-(m Chemical compound C1[C@H](OC)[C@@H](N(CC)C(C)=O)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@@](C/3=C/CSSC(C)(C)CC(=O)N\N=C(/C)C=3C=CC(OCCCC(N)=O)=CC=3)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HNMATTJJEPZZMM-BPKVFSPJSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 229960002530 sargramostim Drugs 0.000 description 1
- 229940053186 sclerosol Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000849 selective androgen receptor modulator Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 201000006476 shipyard eye Diseases 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical class [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 229950001248 squalamine Drugs 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000005082 stem growth Effects 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229940034785 sutent Drugs 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
- 229940061353 temodar Drugs 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 239000003439 teratogenic agent Substances 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical group CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
- DKACXUFSLUYRFU-UHFFFAOYSA-N tert-butyl n-aminocarbamate Chemical compound CC(C)(C)OC(=O)NN DKACXUFSLUYRFU-UHFFFAOYSA-N 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960002784 thioridazine Drugs 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000003558 transferase inhibitor Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 229940086984 trisenox Drugs 0.000 description 1
- ZNRGQMMCGHDTEI-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CNC2=C1 ZNRGQMMCGHDTEI-ITGUQSILSA-N 0.000 description 1
- 229960003688 tropisetron Drugs 0.000 description 1
- 208000022271 tubular adenoma Diseases 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229940001814 uvadex Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000016788 valerian Nutrition 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- 229940054937 valstar Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940099039 velcade Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229940065658 vidaza Drugs 0.000 description 1
- 208000009540 villous adenoma Diseases 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229960000237 vorinostat Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940053867 xeloda Drugs 0.000 description 1
- 150000003746 yttrium Chemical class 0.000 description 1
- 229940053890 zanosar Drugs 0.000 description 1
- IPSRAFUHLHIWAR-UHFFFAOYSA-N zinc;ethane Chemical compound [Zn+2].[CH2-]C.[CH2-]C IPSRAFUHLHIWAR-UHFFFAOYSA-N 0.000 description 1
- 229960004276 zoledronic acid Drugs 0.000 description 1
- 229940061261 zolinza Drugs 0.000 description 1
- 229940002005 zometa Drugs 0.000 description 1
- 229940088909 zyloprim Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
200901987 九、發明說明: 【發明所屬之技術領域】 本發明係關於作為音速刺蝎蛋白(s〇nic Hedgeh〇g)路徑 抑制劑,尤其Smo拮抗劑之三唑衍生物。因此,本發明之 化合物適用於治療與異常刺蝎蛋白路徑活化相關之疾病, 包括癌症’例如基細胞癌、神經管胚細胞瘤、前列腺癌、 騰腺癌、礼癌、結腸癌、骨癌及小細胞肺癌及上gi道癌。 【先前技術】 f
刺蜎蛋白(Hh)係最先在果蠅似叩⑹幻中發現之分泌 J·生L號轉導蛋白。其為高度疏水性蛋白質,在分泌後可在 組織中擴散及建立梯度,其在胚胎正常發育中具有極為重 要的作用在人類中已鐘別三種具有不同空間及時間分布 模式之册同系物:音速刺螺蛋白(麵)、印度刺螺蛋白 (IHH)及沙漠刺蜎蛋白(DHH)。
Hh信號轉導級聯在Hh結合其受體斑片(p剛後起動。在 無Hh存在下,Ptch抑制另一跨膜蛋白,圓滑蛋白(㈣之 活性,為Hh信號轉導之關鍵介體。—具有類姆 白偶合受體(GPCR)超家族之結構,但不涉及任何Hh結 口 s Hh存在時,其結合ptch以形成無活性複合物,從而 消除Μ對如❶之抑制作用且活化册反應路徑。接著職 號經由蛋白複合物在果繩中傳送至轉錄因子前臂中斷 ㈣伽interrupt ’ Ci)及在哺乳動物中傳送至犯轉錄因 子。在無Hh信號轉導存在下,α裂解且胺基末端片段充當 Hh把基因轉錄之抑制劑。在剛言號轉導之後,。裂解被 i30071.doc 200901987 阻止且Ci成為靶基因轉錄之活化劑。 雖然SHH信號轉導之胚胎缺失可能導致獨眼畸形及其他 發育缺陷(Chiang C等人383:407-413 (1996)),但咸 信SHH路徑之不當活化將導致細胞增殖增加及腫瘤形成且 與許多不同類型之惡性疾病相關,該等惡性疾病包括基細 胞癌(BCC)、神經管胚細胞瘤、胰腺癌、小細胞肺癌、前 列腺癌(pc)、乳癌、消化道腫瘤及皮膚癌(Kisely〇v AS Anti-cancer Agents in Medicinal Chemistry 6:445-449 (2006)及 Sidransky D iVaiwre 14:7-8 (1996))。因 此’ Hh路徑為多種病狀之重要藥理學標靶。 癌症中Hh路徑之異常活化被視為係由路徑中之突變(配 位體獨立性)或由Hh過度表現(配位體依賴性)所引起。
Ptch 1中之突變已與痣樣基細胞癌症候群(亦稱為戈林症 候群(Gorlin syndrome))相關聯,其係一種特徵為多種發育 缺陷及發展多種基細胞癌(BCC)、神經管胚細胞瘤、橫紋 肌肉瘤及數種其他贅瘤之素因的病狀。在偶發性BCC及神 經管胚細胞瘤及多種其他偶發性腫瘤中亦已發現鈍化ptch 且活化 Smo之突變(Reifenberger J等人 Ca«cer 58:1798-1803 (1998)及 Xie J 等人iVaiwre 391:90-92 (1998))。 植物源致畸形生物鹼西洛帕明(cyclopamine)及芬芬驗 (jervine)已證明藉由結合Smo(Chen JK等人z>ev. 1 6:2743-2748 (2002))直接抑制 SHH信號轉導(c〇〇per MK 等 人 Scz.wce 280:1603-1607 (1998)及 Incardona JP 等人 Deve/opmwi 125:3553-3562 (1998))引起前腦無裂畸形。活 130071.doc 200901987 體外測試已展示致畸劑西洛帕明可抑制來自Ptch"·小鼠數 種神經膠母細胞瘤/神經膠質瘤細胞株、神經管胚細胞瘤 細胞株、鱗狀細胞癌細胞株及SCLC細胞株之纖維母細胞 之異常細胞生長(BakM等人P/7β|·;77(3c·¢?^r¢wc>wks4(4):411-429 (2003))。西洛帕明亦已在活體内在神經管胚細胞瘤模 型中展現功效(Dahmane N等人 Deve/opweW 128:5201-5212 (2001) 及 Berman CM 等人 Scz'ewce 297:1559-1561 (2002))。 已在SHH反應性細胞模型中鑑別合成Hh拮抗劑,其中一些 祀向 Smo(Chen JK 等人 Proc· Α/αί/. Jcat/· 5W. [/以 99:14071-14076 (2002),Frank-Kamenetsky Μ等人J. 1:10 (2002)及 Williams JA 等人/Voc. Wai/. dead 5W, tASd 100:4616-4621 (2003))而其他則乾向Smo下游的未知標起 (Chen JK等人/V〇c. dead· *SW. t/M 99:14071-14076 (2002) )。 報導已展示在廣泛範圍之人類腫瘤活組織檢查切片及細 胞株(包括小細胞肺癌、胰腺癌、食道癌、胃癌及膽道 癌、前列腺癌、乳癌、結腸癌及肝癌)中偵測到Hh過度表 現,有時伴隨Hh靶基因表現增加(Rubin ll等人胸仏〜 £)^cove〇; 5:1026-33 (2006))。 US 2006/04〇459描述作為適用於治療代謝病症之1型u_ β-羥基類固醇脫氫酶(lip_HSD1或HSD1)抑制劑之特定三 口伞 〇 現意外發現此等化合物為Hh路徑之抑制劑,尤其為如〇 拮抗劑。 I30071.doc 200901987 【發明内容】 本發明提供結構式I之化合物: r1r2r3c
或其醫藥學上可接受之睡布.、交澈丨八 心…“ 一“劑合物用於製造治療或預防 了由W拮抗作用改善之病狀之藥劑之用途,其中:
中之兩者表錢原子,且另_者表*氧原子; 與其所連原子-起表示視情況經卜2個氟原子取代 之環丁基環,且R3表示氫或氟原子; 或 R1表示甲基; R2表示甲基或氟原子;且 R3表示氟原子。 本發明亦提供一種治療或預防可由Sm〇拮抗作用改善之 病狀之方法,該方法包含向有需要之患者投與有效量之式 I化合物或包含式I化合物之組合物。 本發明亦提供式I化合物或其醫藥學上可接受之鹽或溶 劑合物用於製造治療或預防癌症之藥劑之用途。 本發明亦提供一種治療或預防癌症之方法,該方法包含 向有需要之患者投與有效量之式丨化合物或包含式〗化合物 之組合物。 在一實施例中,X及Y之一為〇且另一者為N,且Z為N。 130071.doc -10· 200901987 在另一實施例中,X為Ο,Y為N且Z為N。 在另一實施例中,RI為甲基,R2為氟且R3為氟。 /另-實施例中,RjR2與其所連原子_起形成經㈣ 鼠原子取代之環丁基環,且R3為氫。 —在另一實施例中’…及尺2與其所連原子—起形成3,3-二 氟環丁基,且R3為氫。 本發明亦提供結構式Π之化合物:
或其醫藥學上可接受之鹽或溶劑合物用於製造治療或預防 可由Smo拮抗作用改善之病狀之藥劑之用途,其中:r|、 R2及R3係如上文所定義。 關於式Π之較佳識別係如先前關於幻所定義並加以必要 的變更。
J 本發明亦提供化合物: 5-(1,1-二氟乙基甲基_5_[2_(三氟甲基)苯基]_4H_ 1,2,4-三唑_3_基}雙環[2 2 2]辛小基二唑. 或其醫藥學上可接受之鹽或溶劑合物用於製造治療與^ 拮抗作用相關之疾病(諸如癌症)之藥劑之用途。 本發明亦提供化合物: 5-(3,3-^ ^ T ^)-3-(4.{4.f ^.5.[2_(^ ^ f 或其醫藥學上可接受之鹽或溶劑合物用於製造治療與— 130071.doc 200901987 拮抗作用相關之疾病(諸如癌症)之藥劑之用途。 本發明亦提供化合物: 5-0-氟小甲基乙基)-3_(M4_甲基_5_[2_(三氟甲基)苯基]· ㈣二心三嗤-3_基}雙環[2.2.2]辛小基m,2,4_鳴二唑; 或其醫藥學上可接受之鹽或溶劑合物用於製造治療與— 拮抗作用相關之疾病(諸如癌症)之藥劑之用途。 本發明亦提供化合物:
2H-二4乙基)-5-(4-{4_甲基_5·[2_(三氟曱基)苯基]_4h_ 1,2,4-三吐-3-基}雙環基)],3,4-嗯二唑; 或其醫藥學上可接受之鹽或溶劑合物用於製造治療與化。 拮抗作用相關之疾病(諸如癌症)之藥劑之用途。 本發明亦提供化合物: 2-(3,3_二氣環丁基)-5-(M4_甲基·5例三氟甲基)苯基]_ .U〆-三唾_3.基}雙環[2 2 2]辛小基-嗔二唑; 或其醫藥學上可接受之鹽或溶劑合物用於製造治療與— 拮抗作用相關之疾病(諸如癌症)之藥劑之用途。 本發明亦提供化合物: 2-U-氟-卜曱基乙基)-5_(M4_甲基_5_[2_(三敗甲基)苯基]_ 4H_1,2,4-三唑_3_基}雙環[2·2.2]辛小基)],3,4-噁二唑; 或其醫藥學上可接受之睡$、、六杰,丨 J按又之鹽或,谷劑合物用於製造治療與Sm〇 拮抗作用相關之疾病(諸如癌症)之藥劑之用途。 本發明之料内亦包括上述Μ化合物之^氧化物。通 常’該等Ν-氧化物可在任何可用氮料上形成。Ν_氧化物 可藉由習知方式形成,諸如使式“匕合物在濕氧化銘存在 130071.doc -12- 200901987 下與過硫酸氫卸反應。 本發明之範疇内包括上述式I化合物之前藥。通常,該 等前藥將為易於在活體内轉化為所需式j化合物的式j化合 物之官能衍生物。選擇及製備合適前藥衍生物之習知程序 描述於(例如)"Design of Pr〇drugs" ’ H Bundgaard編,
Elsevier,1985 中。 如藥可為需要在體内轉化以釋放活性藥物且具有優於母 藥分子之改良傳遞特性之生物活性物質("母藥"或"母分子") 之藥理學無活性衍生物。活體内轉化可(例如)為某種代謝 過程之結果,諸如羧酸酯、磷酸酯或硫酸酯之化學或酶促 水解,或敏感官能基之還原或氧化。 本發明之範疇内包括式I化合物及其鹽之溶劑合物,例 如水合物。 本發明之化合物可具有不對稱中心、對掌性軸及對掌性 平面(如 E.L. Eliel及 S.H. Wilen,⑽c/2㈣Μ” ⑽ 績也 John Wiley & s〇ns,心…γ_,i994,第"a 1190頁中所述)且可以外消旋體、外消旋混合物及以個別 非對映異構體形式存在’所有可能的異構體及其混合物, 包括光學異構體、所有該等立體異構體均包括於本發明 内。另外’本文所揭示之化合物可以互變異構體形式存在 且儘管僅描述一種互變異構結構,但兩種互變異構形式均 意欲涵蓋於本發明之範嘴内。 該等化合物可以不同異構形式存在,所有㈣異構形式 均涵蓋於本發明内。 130071.doc 13 200901987 結構式!之化合物可(例如)藉由自合適溶劑(例如τ醇或 乙酸乙酿或其混合物)分步結晶或經由使用光學活性固定 相之對旱性層析來分離為其個別非對映異構體。絕對立體 =學可藉由結晶產物或所衍生之結晶中間物的㈣線結晶 予(若必要)利用含有已知絕對構型之不對稱中心的試劑來 判定。 或者,-般結構式!之化合物之任何立體異構體可使用 學純起始物質或具有已知絕對構型之試劑藉由立體特定 合成來獲得。 該等化合物可以多種不同多晶型存在。 式I化合物之游離鹼及其醫藥學上可接受之鹽及立體異 構體均包括於本發明内。本發明之化合物可在胺及/或含Ν 雜每部分之Ν原子處經質子化以形成鹽。術語"游離驗”传 指非鹽形式之胺化合物。所涵蓋之醫藥學上可接受之趟不 僅包括關於本文所述之转定 ^ 4之特疋化合物所例示之鹽,而且包括 式I化合物游離形式之所有典型醫藥學上可接受之睡。所 =述之特定鹽化合物之游離形式可使用此項技術中已知之 =來分離。舉例而言’游離形式可藉由用合適稀驗水溶 ^如稀Ν3〇Η、碳酸鉀、氨及碳酸氣鈉水溶液)處理鹽來 生;涛離形式與其各別鹽形式的些許區別在於某些物理 =,諸如於極性溶劑中之溶解度,但對於本發明而言酸 ^及驗式鹽在其他方面在醫藥學上等效於其各別游離形 可藉由習知化學方法白人亡 自3有鹼性邛分之本發明化合物合 130071.doc 200901987 成本發明化合物之醫藥學上可接受之鹽。通常,藉由離子 交換層析或藉由使游離鹼與化學計量之量或過量之所需成 鹽無機酸或有機酸於合適溶劑或各種溶劑組合中反應來製 備驗性化合物之鹽。
因此’本發明化合物之醫藥學上可接受之鹽包括本發明 化合物之習知無毒性鹽,其係藉由使本發明鹼性化合物與 無機酸、有機酸或聚合酸反應來形成。舉例而言,習知無 毒性鹽包括衍生自諸如鹽酸、氫溴酸、氫碘酸、硫酸、亞 硫酸、胺基磺酸、磷酸、亞磷酸、硝酸及其類似物之無機 酸之鹽’以及自諸如順丁烯二酸、雙羥萘酸、羥基順丁烯 二酸、麵胺酸、水揚酸、甲苯磺酸、曱烷碘酸、乙烷二磺 酸、草酸、天冬胺酸、乙烷磺酸、乙烷二磺酸、三氟乙酸 及其類似物之有機酸製備之鹽。合適聚合鹽之實例包括衍 生自諸如鞣酸、羧基甲基纖維素之聚合酸之鹽。較佳地, 本發明之醫藥學上可接受之鹽含有i當量式⑴化合物及j、 2或3當量無機酸或有機酸。更特定言之,本發明之醫藥學 上可接焚之鹽為三氟乙酸鹽或氣化物鹽。在一實施例中, 鹽為三氟乙酸鹽。在另一實施例中,鹽為氣化物。 上述醫藥學上可#受之鹽及其他典型冑藥學i可接受之 鹽的製備更詳細描述MBerg等人〇977) /以 66:1_19 中。 亦應主思本發明之化合物可能為内鹽或兩性離子,因為 在生理條件下化人物φ夕丄# 1 , 中之去質子化酸性部分(諸如羧基)可 為陰離子性的,而此雷科开各 此冤何可旎在内部抵消質子化或烷基化 130071.doc 200901987 驗性部分(諸如四級氮原子)之陽離子電荷。 本發月之化合物可單獨或與醫藥學上可接受之載劑、賦 』,稀釋制、佐劑、填充劑、緩衝劑、穩定劑、防腐 劑、潤滑劑組合以磐縫 、一 乂面樂組合物形式根據標準醫藥實務投與 哺乳動物(較佳人類)。 本發月之化合物可藉由任何適宜投藥途徑全身性/外周 性^在所需作用部位投與受檢者,包括(但不限於)口服(例 如藉由攝取);局部(例如 g枯、4皮、鼻内、眼、類及壬 、下);肺(例如藉由估用〜丨1、产 古 入或吹入療法);直腸.降、# · ^ 飞鼻之及 腸’陰道’非經腸(例如藉由注射,包 括皮下、皮内、肌肉内、 ^ 靜脈内、動脈内、心内、鞘内、 舍柱内、囊内、囊下、眶内、腹膜内 關節内、蛛網臈下及胸骨 s 、皮下、 在皮下或肌肉内)。 ),及精由植入藥物儲槽(例如 J檢者可為真核生物、動物'脊椎動物、 ω動物(例如,豚鼠、 動物、备 瓦虱、大鼠、小鼠、、 如,小鼠)、女抖叙輪/ 鼠科動物(例 鼠)大科動物(例如,狗)、貓科 馬科動物(例如,馬)、$ (例如’貓)、 J逮長類動物、猿(例1 猿)、猴(例如,狨猴、狒挑 ,猴或類人 想很 弗狒)、類人猿(例如,大 ㈣、獲獲、長臂猿)或人類。 大猩獲、黑 =明亦提供包含1多種本發明之 可接受之載劑之醫藥組合物。含有活性成份=樂學上 可為適用於口服應用之 之酉藥組合物
v式,例如錠劑、D人A 水性或油性懸浮液、可 3錠、含片、 刀放之粉末或顆粒、 礼硬、硬膠囊 130071.doc 200901987 2膠囊、或糖漿或酏劑。可根據製造醫藥組合物之技術 …夫之任何方法來製備意欲用於口服應用之組合物,且 4專組合物可含有—或多種選自由以下各物組成之群之藥 …甜味劑、調味劑、著色劑及防錢,讀提供醫藥學 上優良且適口之贺碼〖 Μ ^ 性醫藥學上可接適用於製造_之無毒 又之賦形劑混合之活性成份。此等賦形劑 可為(例如)惰性稀釋劑,諸如碳酸詞、碳酸納、乳糖、鱗 _或她;成粒劑及崩解劑,例如微晶纖維素、交聯 趣甲纖維素納、玉米殿粉或褐藻酸;黏合劑,例如殿粉、 明膠、聚乙婦口比略㈣或阿拉伯膠;及潤滑劑,例如硬脂 酸鎮、硬脂酸或滑石。趁劑可未經包衣或其可藉由已知技 術包衣以掩蔽藥物之不良味道或延遲在胃腸道内之崩解及 吸收,且藉此提供較長時間内之持續作用。舉例而士可 使用諸如經丙基甲基纖維素或經丙基纖維素之水溶崎味 材料,或諸如乙基纖維素、乙酸丁酸纖維素之延時材料。 u 供口服應用之調配物亦可呈現為硬明膠膠囊形式,其中 將活性成份與例如碳_、磷㈣或高嶺土之惰^固體稀 釋劑混合;或呈現為軟明膠膠囊形式,其中將活性成份血 諸如聚乙二醇之水溶性載劑或例如花生油、液體石壤或橄 欖油之油介質混合。 水性懸浮液含有與適用於製造水性懸浮液之賦形劑混入 的活性物質。料賦形劑為懸浮劑,例如Μ基纖_ 納、甲基纖維素、經丙基甲基纖維素、褐藻酸納、聚乙炼 。比…、黃箸膠及阿拉伯冑;分散劑或潤满劑 130071.doc 200901987 然產生之鱗脂,例如印磷脂,或氧化婦與脂肪酸之縮合產 物,例如聚氧乙婦硬脂酸醋,或氧化乙稀與長鍵脂族醇之 纩。產物例如十七伸乙基氧基録壤醇,或氧化乙稀與衍 生自脂肪酸及己聽醇之偽陆 哔您偏自日的細合產物,諸如聚氧乙烯山 梨糖醇單油酸醋,或氧化乙婦與衍生自脂肪酸及己酷醇軒 偏-曰的縮口產物’例如聚乙烯脫水山梨糖醇單油酸醋。 Γ ^ &亦可含有_或多種例如對經基苯甲酸乙醋或對 羥基苯甲酸正丙醋之防腐劑、一或多種著色劑、一或多種 調味劑及-或多種諸如魏、糖精或阿斯巴甜糖之甜味 劑。 '油«浮液可藉由將活性成份懸浮於例如花生油、橄欖 油、芝麻油或椰子油之植物油中或諸如液體石峨之擴物油 中來調配。油性懸浮液可含有增稠劑,例如蜂蟻、硬石蠟 或紅蠘醇。可添加諸如以上所列之甜味劑及調味劑以提供 適口之口服製劑。可藉由添加諸如丁基化經基大茵香喊或 α-生育紛之抗氧化劑來保存此等組合物。 適用於藉由添加水來製備水性懸浮液之可分散粉末及顆 拉提供與分散劑或濕潤劑、懸浮劑及一或多種防腐劑混合 之’舌I·生成伤。合適分散劑或濕潤劑及懸浮劑由上文已提及 /等丨τ亦可存在其他賦形劑,例如甜味劑、調味劑 ^著^,卜可藉由添加諸如抗壞錢之抗氧化劑 此 4組合物。 可HZ之醫藥組合物亦可為水包油型乳液之形式。油相 …、物油(例如,橄欖油或花生油)或礦物油(例如,液體 130071.doc -18- 200901987 石增* )或此專物暂夕、、日 物質之此σ物。合適之乳化劑可為天然產生 之磷脂(例如,大豆卩磁 穴卵磷知)及衍生自脂肪酸及己醣醇酐之 酉曰或偏自日(例如,脫水山梨糖醇單油酸醋)及該等偏醋與氧 t /縮σ產物(例如,聚氧乙烯脫水山梨糖醇單油酸 8曰)。礼液亦可含有甜味劑、調味劑、防腐劑及抗氧化 劑。 ▲減及㈣j可使用甜味劑,例如甘油、丙二醇、山梨糖 醇或蔑糖調配。該耸鋼耐& + 1 λ 这4調配物亦可含有緩和劑、防腐劑、調 味劑及著色劑以及抗氧化劑。 醫藥、·且σ物可為無菌可注射水溶液之形式。可接受之媒 劑及溶劑中可使用水、林格氏溶液⑻㈣〜。iuti〇n)及等 張氣化鈉溶液。 無菌可注射製劑亦可為活性成份溶解於油相中之無菌可 注射水包油型微乳液。舉例而言,可首先將活性成份溶解 於大豆油與㈣脂之混合物中。接著將油溶液引入水與甘 油混合物中且經處理以形成微乳液。 可注射之溶液或微乳液可藉由局部快速注射引入患者血 流内。或者,可有利地以使得維持本發明化合物之怪定循 環濃度之方式投與溶液或微乳液。為維持該恒定濃度,可 利用連續靜脈内傳遞裝置。該裝置之實例為De^ c細^ PLUS™型5400靜脈泵。 醫藥組合物可為用於肌肉内及皮下投藥之無菌可注射水 性或油性懸浮液之形式。此懸浮液可使用上文已提及之彼 等合適分散劑或濕潤劑及懸浮劑根據已知技術來調配。無 130071.doc 200901987 困可注射製劑亦可為於益毒 劑中 …、母性非,!腸可接欠之稀釋劑或溶 .‘,,、痛可注射溶液或懸浮液,例如為於丨,3_丁二醇中 之溶液。此外,習知@ . 、、Λ八 用無鹵 '不揮發性油作為溶劑或懸 汙"質。對此而言,可使用人。 便用包括口成早甘油酯或二甘油酯 之任何無刺激性不揮發性、法。 / 另外,啫如油酸之脂肪酸亦 可用於製備注射劑。 /式1化合物亦可以栓劑形式投與以供直腸投與藥物。可 藉由將藥物與在當、;+ 興隹常,凰下為固體但在直腸溫度下為液體且因 此將在直腸中融化以釋放藥物的合適非刺激性賦形劑混合 來製備此等組合物。該等材料包括可可脂、甘油明膠、氫 化植物油、多種分早暑夕取r t 1 里之1乙一醇之混合物及聚乙二醇之 脂肪酸酯。 對於局部應用而言,可使用含有式I化合物之乳膏、軟 膏、凝膠、溶液或懸浮液等。(對於此施用而言,局部施 用可包括漱口劑及含漱劑)。 本發明之化合物可經由局部使用合適鼻内媒劑及傳遞裝 置以鼻内形式’或經由經皮途徑使用普通熟習此項技術者 熟知之經皮貼片之彼等形式投與。對於以經皮傳遞系統之 形式投與,在整個劑量方案中劑量投與當然將為連續而非 間斷的。亦可使用諸如可可脂、甘油明膠、氫化植物油、 多種分子量之聚乙二醇之混合物及聚乙二醇之脂肪酸酿之 基質以检劑形式傳遞本發明之化合物。 當將本發明之化合物投與受檢者時,所選劑量將視多種 因素而定,包括(但不限於)特定化合物之活性、個體症狀 13007 丨.doc •20- 200901987 :=:?!途徑'投藥時間、化合物排泄速率、治療 串者之年龄且σ使用之其他藥物、化合物及/或物質以及 患者之年齡、性別、體重、 扃狀、一般健康情況及先前病 史。化&物之量及投藥途徑最終將由醫師決定’但通常叫 量將在作用部位達到可達 艰吊j 有害副作用之局部濃度。作用而不造成實質傷害或 在整個治療過程中,,,壬辨 π 體内技樂可以連續或間斷投盥—
個劑量(例如以合適間隔分次投藥)。確定投藥最有效方式 及劑量之方法為熟習此項技術者所熟知且將隨療法所用調 配物、療法目@、所治療靶細胞及所治療受檢者而變化。 可進行單次或多次投藥,其中劑量及方式由治療醫師選 疋通常活性化合物之合適劑量在每天每公斤受檢者體 重約100 pg至約250 mg之範圍内。若活性化合物為鹽、 醋、前藥或其類似物時,投藥量係以母化合物為基準計 算’因此按比例增加所使用實際重量。 本發明提供抑制刺螺蛋白信號轉導路徑之活化,(例如) 以抑制由諸如Pteh功能缺失、㈣蛋白功能獲得、圓滑蛋 白功能獲得或Gli功能獲得之表型所導致之異常生長狀態 之方法’ λ包括使細胞與足以促進正常化活性、括抗正 常刺蜎蛋白活性、拮抗圓滑蛋白活性或拮抗GH活性之量 的式I化合物接觸(例如),以逆轉或控制異常生長狀態。 本發明進一步提供治療過度增生性病症(亦即癌症)以及 其他刺*1蛋白路徑介導之病症或病狀,改善其—或多種症 狀或減輕其嚴重性之方法。 130071.doc 21 200901987 已發現許多腫瘤及增生性病狀與刺蜎蛋白路徑相關。該 等細胞之生長及存活可受到本發明化合物治療影響。舉例 而言,小分子抑制刺蜎蛋白路徑已顯示會抑制基細胞癌 (Williams等人尸见100: 4616-21 (2003))、神經管胚細胞 瘤(Berman 等人《Sc/ewce 297:1 559-6 1 (2002))、膜腺癌、胃 腸癌及食道癌(Berman 等人 iVaiwre 425:846-51 (2003)及 WO 05/013800)、肺癌(Watkins等人iVaiwre 422:313-7 (2003))及 前列腺癌(Karhadkar 等人 iVaiMre 431: 707-12 (2004))之生 長。 另外,已顯示許多癌症類型之刺蜎蛋白路徑之活化作用 已失去控制,例如乳癌(Kubo等人Carwcer /ieiearc/? 64:6071-4 (2004))、肝細胞癌(Patil 等人(2005)第 96 屆 AACR年會(96th Annual AACR conference),摘要 #2942及 Sicklick 等人(2005) ASCO 年會(ASCO annual meeting)’ 摘 要#9610)、血液惡性疾病(Watkins及Matsui,結果未公 開)、基底癌(Bale 等人 fiiiman MoZec. Genet. B:757-762 (2001),Xie等人iVaiwre 391: 90-92 (1998))、神經管胚細胞 瘤(Pietsch等人 Ca加er 心 57: 2085-88 (1997))及胃癌(Ma 等人 Carci’wogewei'z··? 5 月 19 日,(2005) (EPub))。 已知功能障礙性突變斑片基因之表現出現在偶發性及家 族性BCC中。亦已在偶發性神經管胚細胞瘤、腦膜瘤、乳 癌、食道鱗狀細胞癌及膀胱腫瘤中發現斑片基因突變或缺 失(Oncogene (1998) 17, 1 167-1 172)。 本發明之化合物可用於治療或預防可由Smo拮抗作用改 130071.doc -22- 200901987 善之病狀。本發明之化合物亦適用於製造治療或預防本文 所述疾病之藥劑。 本文所提供之化合物、組合物及方法尤其被認為適用於 治療癌症。可由本發明之化合物、組合物及方法治療之癌 症包括(但不限於)贲門:肉瘤(血管肉瘤、纖維肉瘤、橫紋 肌肉瘤、脂肪肉瘤)、黏液瘤、橫紋肌瘤、纖維瘤、脂肪 瘤及畸胎瘤;肺:支氣管癌(鱗狀細胞癌、未分化小細胞 癌、未分化大細胞癌、腺癌)、肺泡(細支氣管)癌、支氣管 腺瘤、肉瘤、淋巴瘤、軟骨瘤、錯構瘤、間皮瘤;胃腸: 食道(鱗狀細胞癌、腺癌、平滑肌肉瘤、淋巴瘤)、胃(癌 瘤、淋巴瘤、平滑肌肉瘤)、胰腺(胰管腺癌、胰島素瘤、 升糖素瘤、胃泌素瘤、類癌腫瘤、VIP瘤)、小腸(腺癌、 淋巴瘤、類癌腫瘤、卡波西氏肉瘤(Karp〇si,s sarc〇ma)、 平滑肌肉瘤、血管瘤、脂肪瘤、神經纖維瘤、纖維瘤)、 大腸(腺癌、管狀腺瘤、絨毛狀腺瘤、錯構瘤、平滑肌肉 瘤)、結腸、結腸直腸、直腸;泌尿生殖道:腎(腺癌、威 爾姆斯氏瘤(Wilm’s tumor)[腎胚細胞瘤]、淋巴瘤、白血 病)、膀胱及尿道(鱗狀細胞癌、移行細胞癌、腺癌)、前列 腺(腺癌、肉瘤)、睪丸(精原細胞瘤、畸胎瘤、胚胎性癌、 畸胎癌、絨毛膜癌、肉瘤、間質細胞癌、纖維瘤、纖維腺 瘤、腺瘤樣瘤、脂肪瘤);肝:肝細胞瘤(肝細胞癌)、膽管 癌、肝胚細胞瘤、血管肉瘤、肝細胞腺瘤、血管瘤;骨. 骨源性肉瘤(骨肉瘤)、纖維肉瘤、惡性纖維組織細胞瘤、 軟骨肉瘤、尤文氏肉瘤(Ewing's sarcoma)、惡性淋巴瘤(網 130071.doc •23- 200901987 織細胞肉瘤)、多發性骨髓瘤、惡性巨細胞瘤索脊瘤、骨 軟骨瘤(骨軟骨外生性骨疢)、良性軟骨瘤、軟骨母細胞 廇軟月黏液纖維瘤、骨樣骨瘤及巨細胞瘤;神經系統: (月瘤血^瘤、肉芽瘤、黃瘤、畸形性骨炎)、腦膜 (,腦膜瘤、腦膜肉瘤、神經膠質瘤病)、腦(星細胞瘤、神經 S胚、’、田胞瘤、神經膠質瘤、室管膜瘤、胚組織瘤[松果體 瘤]、多形性神經膠母細胞瘤、少突神經膠質瘤、神經鞘 瘤視、.,罔膜胚細胞瘤、先天性腫瘤)、脊髓(神經纖維瘤、 、 職瘤、神經膠質瘤、肉瘤);婦科:子宮(子宮内膜癌)、 子呂頌(子宮頸癌、腫瘤前子宮頸發育不良)、印巢(印巢癌 [水液11囊腺癌、黏液性囊腺癌、未分類癌]、粒層泡膜細 胞瘤支持-間質細胞瘤、無性細胞瘤、惡性畸胎瘤)、陰 門(鱗狀細胞癌、上皮内癌、腺癌、纖維肉瘤、黑素瘤)、 陰C (透明細胞癌、鱗狀細胞癌、葡萄狀肉瘤(胚胎性橫紋 肌肉瘤)、輸即管(癌瘤);血液科:血液(骨髓性白血病[急 性及慢性]、急性淋巴母細胞白血病、慢性淋巴細胞白血 ,$、骨髓增生性疾病、多發性骨_、㈣發育不良症候 群)、霍奇金氏病(Hodgkin,s disease)、非霍奇金氏淋巴瘤 [惡性淋巴瘤];皮膚:惡性黑素瘤、基細胞癌、鱗狀細胞 癌卡波西氏肉瘤、胎記發育不良疲、、脂肪瘤、血管瘤、 皮膚纖維瘤、瘋痕瘤、牛皮癬;及腎上腺:神經母細胞 瘤。因此’如本文所提供之術語"癌細胞,,包括罹患以上鑑 別之病狀中任一者之細胞。 在-實施例中,本發明之化合物可用於治療或預防選自 130071.doc •24- 200901987 以下之癌症:基細胞癌、神經管胚細胞瘤、前列腺癌、胰 腺癌、乳癌、結腸癌、小細胞肺癌、肉瘤、淋巴瘤、白血 病、胃腸癌、多發性骨髓瘤、神經膠質瘤及肝細胞癌。可 由本發明之化合物治療或預防之其他癌症包括偶發性及家 族性基細胞癌、偶發性神經管胚細胞瘤、腦臈瘤、乳癌、 食道鱗狀細胞癌及膀胱癌。 ㈣刺螺蛋白路徑已展示可改善牛皮癣之症狀等人, 20q: 126-131 (2004)及 US 2004/0072913)。 〇 本發明提供式1化合物用於製造治療或預防牛皮癖之藥 劑之用途。 本發明亦提供一種治療或預防牛皮癣之方法,該方法包 含向有需要之患者投與有效量之式!化合物或包含式丨化合 物之組合物。 刺蜎蛋白活化已展示可刺激血管新生(p〇la等人胸⑼以 7(6):706·711(2〇〇1)及 Nagase 等人仏㈣ μ。山 p 10(6):595-604 (2005))且因此充當刺蜎蛋白拮抗劑之化合 物可適用作血管新生拮抗劑。 本發明提供式I化合物用於製造治療或預防血管新生之 藥劑之用途。 本發明亦提供一種治療或預防血管新生之方法,該方法 包含向有需要之患者投與有效量之式j化合物或包含式j化 合物之組合物。 可由式I化合物治療或預防之由血管新生引起、支持或 與其相關之疾病包括癌症、眼部新生血管性疾病、年齡相 130071.doc -25- 200901987 關性黃斑變性、糖尿病性視網膜病、早產兒視網臈病、角 膜移植物排斥反應、新生血管性t光眼、晶狀體後纖維素 增生、流行性角膜結膜炎、維生素A缺乏病、隱形眼鏡超 戴症、遺傳性角膜炎、上角膜緣角膜炎、翼狀胬肉乾燥性 角膜炎、修格氏病(Sjogren's)、痤瘡、水皰性結膜炎、梅 毒、分枝桿菌感染、脂質變性、化學燒傷、細菌性潰瘍、 真菌性潰瘍、單純疱疹感染、帶狀疱疹感染、原生動物感 染、卡波西氏肉瘤、蠶蝕性潰瘍、特瑞恩氏邊緣性變性 (Temen’s marginal degenerati〇n)、邊緣性角質層分離、類 風濕性關節炎、全身性狼瘡、多動脈炎、外傷、韋格納氏 類肉瘤病(Wegeners sarcoidosis)、鞏膜炎、史蒂芬-瓊森氏 病(Stevens Johnson disease)、類天疱瘡放射狀角膜切開 術、角膜移植物排斥反應、類風濕性關節炎、骨關節炎慢 性炎症(例如’潰瘍性結腸炎或克羅恩氏病(Cr〇hn,s disease))、血管瘤、奥韋瑞氏病(〇sier_Webe卜Rendu disease)及遺傳性出血性毛細管擴張。 在一實施例中’本發明之化合物適用於治療及預防與斑 片功能缺失相關之癌症。 在另一實施例中’本發明之化合物適用於治療及預防與 圓滑蛋白功能獲得相關之癌症。 式1化合物亦適用作癌症治療之化學及放射致敏劑。其 適用於治療先前已經歷或目前正在經歷或將經歷癌症治療 之哺乳動物°該等其他治療包括化學療法、放射療法、外 科手術或免疫療法(諸如癌症疫苗)。 130071.doc -26- 200901987 本發明之化合物尤其適用於與治療劑、抗癌劑及/或放 射治療劑組合。因此,本發明提供一種同時、單獨或相繼 投藥之本發明之式〗化合物與治療劑、抗癌劑及/或放射治 療劑之組合。本發明之化合物與其他抗癌劑可增效或協同 作用。本發明之化合物與另—抗癌劑之協同組合可允許使 用此等藥劑中-或兩者之較低劑量及/或本發明之化合物 與其他抗癌劑中-或兩者之較低劑量頻率及/或以可降低 ”將藥劑技與交檢者相關之任何毒性而不降低藥劑癌症治 療功效之較低頻率投與藥劑。另彳,協同作用可能產生此 等藥劑治療癌症之改良功效及/鱗低與單獨使用任-藥 劑相關之任何不良或不當副作用。 可根據此項技術中熟知之治療方案投與治療劑、抗癌劑 二或放射療法。熟習此項技術者將清楚瞭解投與治療 別、抗癌劑及/或放射療法 ’、 視所治療之疾病及抗癌劑及/ 或放射療法對該疾病之已知 臨庆®作用而變化。並且,根據熟練 床醫師之認識,治瘆方
^ ^ ’、,、 如,投藥之劑量及時間)可 鑒於所投與治療劑(亦即 ;τ ™ 柷秦生劑或放射)對患者之所觀 不作用及鑒於疾病對所 規 不良反應而變化。 …療劑之所觀察反應及所觀察 施例中,式1化合物可與—或多種選自消n 抗組織胺劑、抗癌劑、 m 酶抑制劑(例如,酪胺酸5即1、治療性抗體及蛋白激 在另… 激酶抑制劑)之藥劑組合投與。 社力實施例中,提供—M门士 丹 1化合物與抗癌劑之組合。、 時、單獨或相繼投藥之式 130071.doc -27. 200901987 與本發明之化合物組合使用之抗癌劑或化學治療劑之實 例可見於V.T. Devita及s. HeUman(編者)之c o/〇„c〇/〇g>;,第6版(2〇〇1年2月 日)Lippincott Williams & WUkins pubnshers 及 w〇 2006/061638中。普通熟習此項技術者將能夠基於所涉及 藥物及癌症之特定特徵來辨別哪些藥劑組合適用。該等藥 劑包括:雌激素受體調節劑、雄激素受體調節劑、類視黃 素受體調節劑、細胞毒素劑/細胞生長抑制劑、抗增殖 劑、異戊烯基蛋白質轉移酶抑制劑、HMG-CoA還原酶抑 制劑及其他血管新生抑制劑、HIV蛋白酶抑制劑、逆轉錄 酶抑制劑、細胞增殖及存活信號轉導之抑制劑、雙膦酸 鹽、芳香酶抑制劑、siRNA治療劑、分泌酶抑制劑、干 擾受體酪胺酸激酶(RTK)之藥劑及干擾細胞週期檢查點之 藥劑。該等藥劑之實例提供於WO 2006/061 638中。 適用於本發明之組合療法中之抗癌劑包括(但不限於): 1)生物鹼,包括微管抑制劑(例如,長春新鹼(Vincristine)、 長春驗(Vinblastine)及長春地辛(Vindesine)等)、微管穩定 劑(例如,太平洋紫杉醇(paclitaxel)[紫杉酌'(Taxol)]及多稀 紫杉醇(docetaxel)、紫杉德(Taxotere)等),及染色質功能 抑制劑,包括拓撲異構酶抑制劑,諸如表鬼臼素(例如, 依託泊苷(Etoposide)[VP-16]及替尼泊苷(teniposide)[VM-26]等),及標靶拓撲異構酶I之藥劑(例如,喜樹鹼 (Camptothecin)及伊立替康(Isirinotecan)[CPT-1 1]等);2) 共價DNA結合劑[烷基化劑],包括氮芥子氣(例如,氮芥 130071.doc -28- 200901987 (Mechloretharnine)、苯丁 酸氮芥(chlorambucil)、環磷醯 胺(Cyclophosphamide)、異環磷醯胺(ifosphamide)及白消 安(busulfan)[邁樂寧(Myleran)]等)、亞硝基脲(例如,卡莫 司汀(Carmustine)、洛莫司汀(Lomustine)及司莫司汀 (Semustine)等)及其他烷基化劑(例如,達卡巴嗪 (Dacarbazine)、羥甲基三聚氰胺、塞替派(Thi〇tepa)及絲裂 黴素(Mitomycin)等);3)非共價DNA結合劑[抗腫瘤抗生 素]’包括核酸抑制劑(例如,放線菌素D(Dactinomycin)[放 線菌素(Actinomycin)D]等)、蒽環黴素(anthracycline)(例 如,柔紅徽素(Daunorubicin)[道諾黴素(Daunomycin)及柔 毛徽素(Cerubidine)]、經道諾紅徽素(Doxorubicin)[阿黴素 (Adrianycin)]及去甲氧柔紅黴素(Idarubicin)[伊達比星 (Idamycin)]等)、蒽二酮(例如,蒽環黴素類似物,諸如[米 托蒽酉昆(Mitoxantrone)]等)、博萊黴素(bleomycin)(爭光黴 素(Blenoxane))等及普卡黴素(plicamycin)(米拉黴素 (Mithramycin))等;4)抗代謝物,包括抗葉酸劑(例如,曱 胺0票吟(Methotrexate)、菲林(Folex)及美沙(Mexate)等)、 嗓呤抗代謝物(例如,6-疏基嗓吟[6-MP,°票令硫醇 (Purinethol)]、6-硫鳥嗓吟[6-TG]、硫嗤0票吟(Azathioprine)、 阿昔洛韋(Acyclovir)、更昔洛韋(Ganciclovir)、氣去氧腺 苷、2-氯去氧腺苷[CdA]及2’-去氧助間型黴素(2,-Deoxycoformycin)[喷司他丁(Pentostatin)]等)、鳴 π定拮抗劑 (例如,氟嘲。定[例如,5-氟尿嘲咬(阿杜辛(Adrucil))、5-氟 去氧尿苷(FdUrd)(氮尿苷(Floxuridine))]等)及胞嘧啶阿拉 130071.doc -29- 200901987 伯糖苷(例如,赛德薩(Cytosar)[ara_c]及氟達拉濱 (FhKlarabine)等);5)酶’包括^天門冬醯胺酶;6)激素, 包括糖皮質激素,諸如抗雌激素(例如,他莫昔芬 (Tamoxifen)等)、非類固醇抗雄激素(例如,敗他胺(Fiu_ide)
等)及芳香酶抑制劑(例如,安美達錠(anastr〇z〇le)[阿那曲 唑(Anmidex)]等);7)鉑化合物(例如,順鉑(cispiatin)及卡 波始(Carb〇platin)等);8)與抗㈣物、毒素及/或放射性核 素等結合之單株抗體;9)生物反應調節劑(例如,干擾素 [例如,IFN-α等]及介白素[例如,IL_2等]等” ι〇)接受性 免疫療法;11)造血生長因子;12)誘導腫瘤細胞分化之藥 齊J (例如王反-視汽酸等),1 3)基因療法技術;丨4)反義療 法技術;15)腫瘤疫苗;16)對抗腫瘤轉移之療法(例如,巴 汀米特(B—)等);17)血管新生抑制劑及激酶抑制 劑0 在-實施例中,用作第二化合物之血管新生抑制劑係選 自酪胺酸激酶抑制劑、表皮源生長因子抑制劑、纖維母細 胞源生長因子抑制劑、血小板源生長因子抑制劑、 MMP(基質金屬蛋白酶)抑制劑、整合素阻斷劑、干擾素· α、介白素-12、多硫酸戊聚糖、環加氧酶抑制劑' 羧醯胺 基三唑、康柏斯達汀(Combretastatin)A_4、角鯊胺、 氯乙醯基-羰基-煙麯黴醇(fumagiH〇1)、沙立度胺 (thahdomide)、血管生長抑素、肌鈣蛋白_丨或針對之 抗體。在一實施例中’雌激素受體調節劑為他莫昔芬或雷 洛昔芬(raloxifene)。 130071.doc -30- 200901987 適用於本發明之組合療法中之治療性抗體包括對抗 HER2蛋白之抗體,諸如曲妥珠單抗(trastuzuinab);對抗生 長因子或生長因子受體之抗體,諸如標無血管内皮生長因 子之貝伐單抗(bevacizurnab)及標乾表皮生長因子之〇si_ 774 ;標乾整合素受體之抗體,諸如維他辛(Vitaxin)(亦稱 為MEDI-522)及其類似物。 在一實施例中,提供一種治療或預防基細胞癌 癌、前列腺癌、肉瘤、淋巴瘤、白血病、胃腸癌、多發性 骨髓瘤、小細胞肺癌、神經膠質瘤、乳癌、肝細胞癌或神 經管胚細胞瘤之方法,該方法包含向有需要之患者投與有 效罝之式I化合物與另一抗癌劑之組合。 在一實施例中,提供一種治療或預防牛皮癬之方法,該 方法包含向t 之患者投與錢f之式【化合物與一或 多種其他抗牛皮癬劑之組合,該等抗牛皮癬劑包括(但不 限於)皮質類固醇、焦油、鈣泊三醇(calcip〇triene卜他紮 羅Wtazarotene)、鈣調神經磷酸酶抑制劑、紫外線輻射、 甲胺嗓τ、類視黃素、環孢素㈣山—心)、免疫調節藥 物、依那西普(etan⑽ept)、阿來法塞⑷咖啡)、依法利 珠單抗(efalizumab)及英利昔單抗(祕_叫。 Z弋之化口物可與放射療法組合使用。術語"放射療法” 2使用電磁或粒子放射治療瘤形成且包括使及 電離放射。 h 13007i.doc 200901987 獨或與放射療法一起使用本發明之化合物引起。為預防或 治療嘔吐,本發明之化合物可與其他止吐劑結合使用,尤 其是神經激肽-1受體拮抗劑;5HT3受體拮抗劑,諸如昂丹 司瓊(ondansetron)、格拉司瓊(granisetron)、托烷司瓊 (tropisetron)及紮替司瓊(zatisetr〇n) ; GABAB 受體激動 劑,諸如巴氯芬(baclofen);皮質類固醇,諸如代卡龍 (Decadron)(地塞米松(dexamethasone))、可那龍(Kenalog)、 阿斯托克(Aristocort)、納沙立德(Nasalide)、布地奈德 (Preferid)、苯可特(Benecorten)或諸如美國專利第2,789,118、 2,990,401 ' 3,048,581 > 3,126,375 ' 3,929,768 ' 3,996,359 ' 3,928,3 26及3,749,712中所揭示之其他藥物;抗多巴胺藥 物,諸如吩噻嗪(例如,丙氣拉嗪(prochl〇rperazine)、氟奮 乃# (fluphenazine)、硫利達嗓(thioridazine)及美索達嗪 (mesoridazine))、曱氧氣普胺(met〇cl〇prarnide)或屈大麻酚 (dronabinol)。在另一實施例中,揭示與選自神經激肽]受 體拮抗劑、5HT3受體拮抗劑及皮質類固醇之止吐劑之聯 合療法用於治療或預防可能因投與本發明化合物所引起的 "區吐。 本發明之化合物亦可與用於治療貧血之藥劑一起投與。 該貧血治療劑為(例如)連續紅血球生成受體活化劑(諸如以 依伯汀(epoetin alfa))。 本發明之化合物亦可與用於治療嗜中性白血球減少症之 藥劑-起投與。該嗜中性白血球減少症治療劑為(例 節嗜中性白血球之產生及功能之造血生長因子,諸如人類 130071.doc •32* 200901987 =細胞群落刺激因子(G_CSF)。G_CSF之實例包括非格司 亭(filgrastim)。 本發明之化合物亦可適用於與s i R N A治療劑組合治療或 預防癌症。 本發明之化合物亦適用於與以下治療劑組合治療癌症: 阿巴瑞克(abarelix)(pienaxis depot®)、阿地白介素 (aldesleiikin)(Pr〇kine®)、阿地白介素(Pr〇leukin®)、阿來組 單抗(Alemtuzumabb)(Campath®)、亞利崔托寧(aiitretin〇in) (Panretin )、別嗓醇(allopurinol)(Zyloprim®)、六甲嘲胺 (altretamine)(Hexalen®)、胺填汀(amifostine)(Ethy〇l®)、安 美達鍵(Arimidex®)、三氧化二坤(Trisenox®)、天門冬醯胺 酶(Elspar®)、阿紮胞苷(azaciticiiiie)(Vidaza®)、貝伐單抗 (Avastin®)、貝瑟羅汀(bexarotene)膠囊(Targretin®)、貝瑟 羅汀凝膠(Targretin®)、博萊黴素(Blenoxane®)、蝴替佐米 (bortezomib)(Velcade®)、白消安靜脈注射劑(Busulfex®)、 白消安口服劑(Myleran®)、卡普睪酮(calusterone) (Methosarb®)、卡培他濱(capecitabine)(Xeloda®)、卡在白 (Paraplatin®)、卡莫司汀(BCNU®、BiCNU®)、卡莫司汀 (Gliadel®)、卡莫司汀與聚苯丙生(Polifeprosan)20移植物 (Gliadel Wafer®)、塞來昔布(celecoxib)(Celebrex®)、西妥 昔單抗(cetuximab)(Erbitux®)、苯丁酸 It 芥(Leukeran®)、 順銘(Platinol®)、克拉屈濱(cladribine)(Leustatin®、2-CdA®)、 氯法拉濱(clofarabine)(Clolar®)、環構醯胺(Cytoxan®、 Neosar®)、環填醯胺(Cytoxan Injection®)、環填醯胺 130071.doc -33- 200901987 (Cytoxan Tablet®)、阿糖胞苷(cytarabine)(Cytosar-U®)、阿 糖胞苷脂質體(DepoCyt®)、達卡巴嗪(DTIC-Dome®)、放線 菌素 D(Cosmegen®)、α達貝汀(Darbepoetin alfa)(Aranesp®)、 柔紅黴素脂質體(DanuoXome®)、柔紅黴素(道諾黴素) (Daunorubicin®)、柔紅黴素(道諾黴素)(Cerubidine®)、地尼 介白素(Denileukin diftitox)(Ontak®)、右雷佐生(dexrazoxane) - (Zinecard®)、多浠紫杉醇(Taxotere®)、多柔比星(doxorubicin) (Adriamycin PFS®)、多柔比星(Adriamycin®、Rubex®)、多 柔比星(Adriamycin PFS Injection®)、多柔比星脂質體 (Doxil®)、丙酸屈他雄酮(DROMOSTANOLONE PROPIONATE) (DROMOSTANOLONE®)、丙酸屈他雄酮(MASTERONE INJECTION®)、依洛特氏 B 溶液(Elliott’s B Solution) (Elliott's B Solution®)、表柔比星(epirubicin)(Ellence®)、α 依伯汀(epogen®)、爾洛替尼(erlotinib)(Tarceva®)、雌莫司 汀(estramustine)(Emcyt®)、填酸依託泊 ^(Etopophos®)、依 託泊苷(VP-16)(Vepesid®)、依西美坦(exemestane)(Aromasin®)、 1 非格司亭(Neupogen®)、氮尿苦(動脈内)(FUDR®)、氟達拉 濱(Fludara®)、氟尿嘧啶(5-FU)(Adrucil®)、氟維司群 , (fulvestrant)(Faslodex®)、吉非替尼(gefitinib)(Iressa®)、吉 西他濱(gemcitabine)(Gemzar®)、吉妥珠單抗奥°坐米星 (gemtuzumab ozogamicin)(Mylotarg®)、乙酸戈舍瑞林 (goserelin acetate)(Zoladex Implant®)、乙酸戈舍瑞林 (Zoladex®)、乙酸組胺瑞林(histrelin acetate)(Histrelin implant®)、經基脲(Hydrea®)、替坦異貝莫單抗(Ibritumomab 130071.doc -34- 200901987
Tiuxetan)(Zevalin )、伊達比星(idamycin®)、異環填醯胺 (IFEX )、甲石買酸伊馬替尼(imatinib mesylate)(Gleevec®)、 α干擾素 2a(Roferon A®)、α干擾素-2b(Intron A®)、伊立替 康(Camptosar )、來那度胺(ienaiid〇mide)(Revnmid®)、雷 曲 σ坐(letrozole)(Femara®)、亞葉酸(ieucovorin)(Wellcovorin®、 Leucovorin )、乙酸免丙立德(LeUpr〇iide Acetate)(Eligard®)、 左旋咪唑(levamisole)(Ergamisol®)、洛莫司汀(CCNU) (CeeBU )、氮介(氮芬子氣)(Mustargen®)、乙酸曱地孕酮 Γ' (megestrol acetate)(Megace®)、美法侖(melphalan)(L- PAM)(Alkeran®)、巯基嘌呤(6-MP)(Purinethol®)、美司鈉 (mesna)(Mesnex®)、美司鈉(Mesnex tabs®) ' 甲胺喋呤 (Methotrexate®)、曱氧沙林(methoxsalen)(Uvadex®)、絲裂 黴素 C(Mutamycin®)、米托坦(mitotane)(Lysodren®) ' 米托 蒽酿>(Novantrone®)、苯丙酸諾龍(nandrolone phenpropionate) (Durabolin-50®)、奈拉濱(nelarabine)(Arranon®)、諾氟珠 單抗(Nofetumomab)(Verluma®)、奥普瑞白介素(Oprelvekin) f , k..’ (Neumega®)、奥沙利銘(oxaliplatin)(Eloxatin®)、太平洋紫 杉醇(Paxene®)、太平洋紫杉醇(Taxol®)、太平洋紫杉醇蛋 白質結合顆粒(Abraxane®)、帕利夫明(palifermin) (Kepivance®)、帕米膦酸鹽(pamidronate)(Aredia®)、培加 酶(pegademase)(Adagen (Pegademase Bovine)®)、培門冬酶 (pegaspargase)(〇ncaspar®)、聚乙二醇化非格司亭 (Pegfilgrastim)(Neulasta®)、培美曲塞二鈉(pemetrexed disodium)(Alimta®)、噴司他丁(Nipent®)、0辰泊漢院 130071.doc -35- 200901987 (pipobroman)(Vercyte®)、普卡黴素(米拉黴素)(Mithracin®)、 卟吩姆納(porfimer sodium)(Photofrin®)、丙卡巴肼 (procarbazine)(Matulane®)、米帕林(quinacrine)(Atabrine®)、 拉布立酶(Rasburicase)(Elitek®)、利妥昔單抗(Rituximab) (Rituxan®)、沙格司亭(sargramostim)(Leukine®)、沙格司 亭(Prokine®)、索拉非尼(sorafenib)(Nexavar®)、鏈佐星 (streptozocin)(Zanosar®)、川頁丁稀二酸舒尼替尼(sunitinib maleate)(Sutent®)、滑石(Sclerosol®)、他莫昔芬(Nolvadex®)、 替莫 11 坐胺(temozolomide)(Temodar®)、替尼泊苦(VM-26)(Vumon®)、睪内赂(testolactone)(Teslac®)、硫鳥嗓呤 (6-TG)(Thioguanine®)、塞替派(Thioplex®)、拓撲替康 (topotecan)(Hycamtin®)、托瑞米芬(toremifene)(Fareston®)、 托西莫單抗(Tositumomab)(Bexxar®)、托西莫單抗/1-1 3 1托 西莫單抗(Bexxar®)、曲妥珠單抗(Herceptin®)、維A酸 (tretinoin)(ATRA)(Vesanoid®)、烏拉莫司汀(Uracil Mustard) (Uracil Mustard Capsules®)、伐柔比星(valrubicin)(Valstar®)、 長春驗(Velban®)、長春新驗(Oncovin®)、長春瑞賓 (vinorelbine)(Navelbine®)、伏立諾他(vorinostat)(Zolinza®) 及0坐來膦酸鹽(zoledronate)(Zometa®) 〇 關於本發明之化合物之術語"投藥"及其變體(例如"投與" 化合物)意謂將化合物或該化合物之前藥引入需要治療之 動物系統内。當與一或多種其他活性劑(例如,細胞毒性 劑等)組合提供本發明之化合物或其前藥時,”投藥”及其變 體分別應理解為包括同時及相繼引入該化合物或其前藥及 130071.doc -36- 200901987 其他藥劑。 欲涵蓋包含指定量之指定 定成份之組合直接或間接 如本文所用,術語,,組合物”意 成份之產物,以及由指定量之指 產生之任何產物。 生12所用之術語"治療有效量”意謂研究員、獸醫、醫 =其他'床診療者所探尋的在組織、系統、動物或人類 中引發生物或醫藥反應之活性化合物或醫藥劑之量。戈人類
λ術°…療癌症"或·'癌纟治療"係指向罹患癌症病狀之哺 礼動物杈藥,且係指藉由殺死癌細胞來減輕癌症病狀之作 用而且係指引起抑制癌症生長及/或轉移之作用。 在未描述中間物及起始材料之合成的情況下,此等化合 物可購得或可自可購得之化合物藉由標準方法或藉由㈣ 本文之上述合成、流程及實例來製備。 法轉化為其他式I化合物 式I化合物可藉由已知方法或藉由本文實例中所述之方 在本文所述之任何合成程序期間,可能必需及/或需要 保濩任何有關分子上之敏感性或反應性基團。此可藉助於 省头保°蔓基來達成,諸如如g Oowp k 办祕e川,第3版,Greene,丁 w及貿此,p G Mm” Interscience,1999 及 K〇cienski,p j 卜〇零 Thieme,1994中所述之保護基。保護基可在適宜後續階段 使用此項技術中已知之方法移除。舉例而言,當存在 Boc(第三丁氧羰基)或苯甲羰基保護基時,其可藉由在約 室溫下添加諸如TFA、DCM及/或MeCN之溶劑來移除。化 130071.doc •37· 200901987 合物亦可使用標準方法,諸如在氫氣氛下在諸如曱醇之溶 劑中用諸如Pd/C之催化劑處理來氫化。亦可在約室溫下在 HC1及1,4-二噁烷存在下添加EtOAc來移除Boc或苯曱羰基 保護基。 當本發明之化合物具有對掌性中心時,可藉由標準分離 方法,諸如使用SFC自外消旋混合物分離非對映異構體。 發現本文所述且經下述檢定測試之例示性化合物具有小 於25 μΜ之IC5G值。 r 說明中所用之縮寫: AIBN:2,2|-偶氮雙異丁腈;BOC:第三丁氧羰基;9-BBN:9-硼雜雙環[3·3.1]壬烷;Bn:苯甲基;nBuLi:正 丁基鋰;Cbz :苯甲氧羰基;CDI : 1,1’-羰基二咪唑; MeOTf :三氟曱烷磺酸曱酯;(C0C1)2 :草醯氯;DAST : (二乙胺基)三氟化硫;DCM :二氯甲烷;DIEA :二異丙基 乙胺;DMAP : 4-(二曱胺基)吡啶;DMC : 2-氣-1,3-二甲 基咪咪鑌氯化物;DMF : N,N-二甲基曱醯胺;Et :乙基; U Et3N :三乙胺;EtOAc :乙酸乙酯;EtOH :乙醇;
Et2Zn :二乙基鋅;FCS :胎牛血清;HATU : 0-(7-氮雜苯 并三唑)-队队^,:^'-四甲基脲鑌六氟磷酸鹽;厘6:曱基; MeCN :乙腈;MeOH :曱醇;mCPB A :間-氣過苯甲酸; MS :質譜;NaOAc :乙酸鈉;NBS : N-溴琥珀醯亞胺; PBS :磷酸鹽緩衝生理食鹽水;Ph :苯基;PyBROP :溴 三吡咯啶基鎮六氟磷酸鹽;PPh3 :三苯膦;pyr :吡啶; SOCl2 :亞硫酸氯;TFA :三氟乙酸;TFFH : N,N,N',N'-四 130071.doc -38- 200901987 甲基曱脒鏽六氟磷酸鹽;THF :四氫呋喃;TLC :薄層層 析;及TsOH :對甲苯磺酸。
Shh-發光II(Shh-Light II)報導體檢定 設計檢定以在同一孔中量測螢火蟲及海腎螢光素酶。 在檢定之前’在生長培養基中培養Shh-發光η細胞 (ATCC 目錄號 CRL-2795)。 檢定方案: 第-1天:在DMSO/抑制劑存在下在檢定培養基中以75 pL/孔接種60,000個Shh-發光II細胞。 第0天:在37。(: 10% C〇2下培育隔夜後添加於水中3 μΜ 嘌呤嗎啉胺(Purmorphamine)(Calbiochem 540220) 〇 第1天:在37°C 10% C〇2下培育30小時後進行檢定,直 接向生長培養基中之細胞: -添加75 μΐ DualGlow螢光素酶試劑(Promega, E2940) -在黑暗中培育1〇 min -在照度計PerkinElmer製造之TopCount上讀盤 _添加 75 μΐ DualGlow Stop & Glow -在黑暗中培育1 〇 m i η -在照度計PerkinElmer製造之TopCount上讀盤 -輸出結果為螢火蟲/海腎計數之間的比值 生長培養基: 對於生長: 〇]\^河:含有〇11(}/1^?乂1'及吡哆醇(018(:0目錄號41966-029)之杜貝卡氏經改良依格培養基(Dulbecco’s Mod Eagle 130071.doc -39* 200901987
Medium)。培養基已補充10% FCS(胎牛血清)、1%青黴素-鏈黴素(10 mg/ml)(GIBCO, 15140-114)及 1% L-麩醯胺酸 200MM(100x)(GIBCO,3042190)及 0.4 mg/ml G418(Roche) 及 0.15 mg/ml 齊奥辛(Zeocyne)(Invitrogen R-250-01)。在 10% co2下培養細胞。 對於檢定: DMEM :含有0.11 G/L Pyr及吡哆醇(GIBCO目錄號 2 1〇63-〇45)而無酚紅之杜貝卡氏經改良依格培養基。培養 基已補充2% FCS(胎牛血清)、1%青黴素-鏈黴素(1〇 mg/ ml) (GIBCO,15140-114)及 1°/。L-麩醯胺酸 200MM(100x) (GIBCO, 3042190)。在 10% C02 0.25% DMSO下培養細 胞。 SHH Smo結合檢定 在經轉染之Cos7細胞中,能夠量測到SMO配位體西洛帕 明-氟棚螢(bodipy)之結合。 檢定方案: ( 第-1天:在10。111皮氏培養皿中接種3,500,000個(:〇87細 胞。 第❶天.用 Lipofectamine2000(Invitrogen)及質體 pSMO-Myc轉染細胞。5小時後在96孔培養盤中在生長DMEM(l〇 % FCS)中接種細胞,每1〇〇 4丨孔15,〇〇〇個細胞。 第1天:轉染後24小時,將培養基變換為檢定DMEM(無 盼紅’ 2% FCS)且添加化合物/0.5% DMSO。在37°C 5% C02下培育。 130071.doc -40- 200901987 第2天:16小時後,添加西洛帕明-氟蝴螢(Toronto Research Chemical, B674800),最終濃度為 50 nM。在 37°C 5% C02下培育4小時。接著用3.5%甲醛以100 μΐ/孔固定細 胞10分鐘。將細胞用PBS洗滌3次且用1.5 μΜ碘化丙啶染色 細胞核。在Acumen探測器上讀數。 -生長培養基: 對於生長: DMEM :含有 0.11 G/L Pyr及"比哆醇(GIBCO, 41966-029) 之GIBCO杜貝卡氏經改良依格培養基。培養基已補充10% FCS(GIBCO, 10106-169)、1% 青黴素-鏈黴素(10 mg/ml) (GIBCO, 15140-1 14)及 1% L-麩醯胺酸 200MM(100x) (GIBCO, 3042190)。在5% C02下培養細胞。 對於檢定: DMEM :含有 0.11 G/L Pyr 及吡哆醇(GIBCO, 21063-045) 而無酚紅之GIBCO杜貝卡氏經改良依格培養基。培養基已 補充 2% FCS(GIBCO, 10106-169)、1°/。青黴素-鏈黴素(10 mg/ml)(GIBCO, 1 5 1 40-1 1 4)及 1 % L-麩醯胺酸 200MM (100x)(GIBCO, 3042190)。在 5% C02 0.5% DMSO下培養細 胞。 對鼠科神經管胚細胞瘤細胞之抗增殖活性 量測Smo拮抗劑抑制原發性同種異體移植物-擴增鼠科神 經管胚細胞瘤細胞增殖之能力。與已建立之腫瘤細胞株相 反,移植後之此等細胞中HH路徑仍保持活性,且腫瘤之 存活/增殖仍維持對HH路徑活化之特異相關性。在無或有 130071.doc -41 - 200901987 合成性Smo激動劑存在下,測定抑制細胞生長5 0%時所需 之濃度(CC50)。 自移植腫瘤獲得神經管胚細胞瘤細胞(Oncogene (2002) 21,75 80-75 84)且以1〇〇,〇〇〇個細胞/毫升之濃度再懸浮於 NPMM中,在100 μί NPMM中以5000個細胞/孔之初始濃度 接種於96孔微量培養盤中。在無或有〇·3 μΜ合成激動劑存 在下,添加經連續稀釋7個點(0.03-25 μΜ濃度範圍,0.25% DMSO)之Smo拮抗劑。接著在37。(3及5% c〇2T,將細胞培 育96 h,且在添加BrdU後再培育24 h。接著固定細胞,且 進行處理以便使用BrdU化學發光免疫檢定套組(R〇che Applied Science目錄號1 1669915〇〇1)按照製造商說明書偵 測與 DNA-結合之 BrdU。使用 Top Coupt儀器(Perkin Elmer) 里測彳δ號,在遞增拮抗劑濃度存在下,依據殘餘Brdu之結 合量測定CC5Q值。 本發明之化合物能夠隨劑量變化之方式抑制神經管胚細 胞瘤細胞增殖。此阻斷作用會受到添加選擇性&。激動劑 而被抑制’此表示可因干擾此等細胞中HH信號轉導而選 擇性抑制增殖作用。無激動劑存在下測得之%值為〇3 μΜ^而添加激動劑使CC5〇值移至大於3〇 在本發明之 狹窄範.内對於所有其他結構相關化合物均可合理預期類 原發性小鼠神經管胚細胞瘤異種
Smo拮抗劑對皮下移植、 移植物生長之作用 檢定本發明 之化合物於活體内抑制刺蜎蛋白 信號轉導相 130071.doc 42· 200901987 關性腫瘤生長之能力。採用以源自出生後受輻射之Ptch-l 雜合小鼠之原發性神經管胚細胞瘤進行之異種移植物模 式。 ' 使源自出生後受輻射之Ptch_/+小鼠小腦之神經管胚細胞 腫瘤(Oncogene (2〇〇2) 21,7580 - 7584)經皮下在活體内連 續繼代。對於此研究’移植腫瘤且在5週齡免疫免疫功能 - 不全小鼠中在50% Matrigel存在下皮下注射神經管胚細胞 瘤細胞之單細胞懸浮液(250萬個細胞/小鼠)。當腫瘤達到 f、 150 mm3之平均體積時’將小鼠隨機化且用在0.5%曱基纖 維素中稀釋之本發明化合物經口以4〇 mg/kg或80 mg/kg每 天治療一次’或以80 mg/kg每天治療兩次。對照小鼠僅用 相同體積之媒劑治療。每週量測腫瘤體積兩次。此實驗表 明本發明之化合物在40及80 mg/kg/天之劑量下引發腫瘤生 長抑制且在80 mg/kg每天兩次之劑量下導致腫瘤收縮。 在本發明之狹窄範疇内對於所有其他結構相關化合物均 可合理預期類似活性。 【實施方式】 實例1
5-(1,1-二氟乙基)-3-(4-(4-甲基·s_【2(三氟甲基)苯基卜4H_ 1,2,4-二唑-3-基}雙環口二…辛+基卜^心喊二唑…⑴ 130071.doc -43 - 200901987 Μ6〇2〇
co2h (1) (CICO)2, dmf ch2ci2_ (2) CH3NH2, THF ch2ci2
Me〇2<? (1)(CICO)2, DMF ch2ci2
cf3 甲苯,回流
1-B 1-Α
KOH, CH3OH H2〇
(1) CDI, CH2CI2 (2) NH4OH
三聚氣化氮 DMF
(1) CH3CF2C02H,
HATU, DIEA, DMF
(2) 110° C, 甲笨或 DMF 步驟A : 在氮氣氛下將4-(甲氧羰基)雙環[2.2.2]辛烷-1-甲酸卜A (Chapman,N. B.等人 J. Org. Chem.,1970,35, 917)(4.0 g, 18.9 mmol)溶解於12 mL無水二氯甲烷中,用草醯氯(於二 氣甲烷中2M,28 mL,56 mmol)處理且隨後用0.5 ml DMF處 理。將反應物在室溫下在氮氣氛下攪拌9〇 min,接著蒸發 且置於真空下歷時2〇 m in。將酸氯化物溶解於無水二氣甲 13007l.doc •44· 200901987 烷(75 mL)中,在冰浴中冷卻,且接著用甲胺溶液(於THF 中2M,57 mL,113 mmol)逐滴處理。添加胺後,移除冷卻 浴且將反應物在周圍溫度下攪拌3〇 min。將混合物用1〇〇〇 mL二氯甲烷稀釋且用〗Ν Ηα水溶液、飽和碳酸氫鈉水溶 液及鹽水洗滌。將有機層經無水硫酸鈉乾燥且蒸發。藉由 急驟矽膠層析,用0-5% MeOH/CH2Cl2梯度溶離來純化產 物以得到呈白色固體狀之4-[(甲胺基)羰基]雙環[2.22]辛 烷-1-甲酸甲酯 1-B。MS (ESI+)=226.2 (M+1)。 步驟B : 將4-[(曱胺基)擬基]雙環[2.2,2]辛烧-1-甲酸甲西旨i_b (2.76 g,12·3 mmol)溶解於二氣甲烷(1〇〇 ml)中,且將草醯氣(於 DCM中2.0 M,15.3 ml)添加至所得溶液中,接著添加 〇ΜΡγ〇·19 ml,2_45 mmol)。接著將反應混合物在室溫下在 氮下攪拌2小時’之後將其濃縮且用曱苯洗脫3次。將殘餘 物再溶解於甲苯(100 ml)中,用5_[2·(三氟甲基)苯基卜1H_ 四唑(3· 15 g,14.7 mmol)處理,且在氮下回流12小時。將 以HC1鹽形式自反應混合物中沈澱出來的產物1,2,4-三唑1 -C溶解於DCM中’用飽和碳酸氫鈉水溶液洗滌兩次,乾燥 (MgS〇4)且洗脫以得到白色固體。MS (ESI+)=394.2 (M+1); Ή NMR (500 MHz, CDC13): δ 2.00 (6H, m), 2.18 (6H, m), 3.48 (3H, s), 3.72 (3H, s), 7.51 (1H, m), 7.71 (2H, m), 7.85 (1H, m) ppm。 步驟C : 在6〇°C下在氮氣氛中將甲酯lcg.w g, 3〇 mm〇1)s5% 130071.doc -45- 200901987 H2O/Me〇H(30 mi)中之溶液用 KOH(0_51 g,9〇 mm〇1)處理 18 h。將所得混合物濃縮,用水(150 ml)稀釋,用Et0Ac^ 滌且用HC1水溶液(1 n)酸化至pH=3。過濾沈澱物,用少量 水及乙謎洗滌且在真空下乾燥以得到粉紅色固體4_{4_曱 基-5-[2-(二氟曱基)苯基]_4H-1,2,4-三嗤-3-基}雙環[2.2.2] 辛烷-1-曱酸(1-D)。NMR (500 MHz,CD3〇D): δ 2.00 (6Η, m), 2.17 (6Η, m), 3.55 (3H, s), 7.62 (1H, m), 7.85 (2H, m),7.96 (1H,m) ppm。 步驟D : 在室溫下在氮氣氛下將一部分固體4-{4-甲基_5_[2-(三氟 甲基)苯基]-4H-1,2,4-三唑-3-基}雙環[2.2.2]辛烷_1_甲酸(1_ D,0.67 g,1.77 mmol)懸浮於 CH2C12(15 ml)中且用 ι',ι,_ 叛 基二咪唑(〇·57 g,3.54 mmol)處理。2 h後,添加濃氫氧化 敍(40 ml)且將反應物攪拌1 8 h。將粗混合物用水(1 5〇 mi) 稀釋且用3份CH:2C12(70 ml)萃取。將有機洗滌液組合,用 鹽水洗滌,經NasSO4乾燥,且在減壓下移除溶劑以得到呈 白色粉末狀之羧醯胺1-E。MS (ESI+)=379.3 (M+1)。 步驟E : 在室溫下在氮氣氛下攪拌羧醯胺1-E(0.64 g,1.7 mmol)及 三聚氯化氰(0.47 g,2.53 mmol)於DMF(15 ml)中之溶液。2 h後’在真空中移除DMF,且將固體再溶解於Ch2C12(1〇〇 ml)中且用飽和碳酸氫鈉水溶液及鹽水洗滌,乾燥 (NadO4),且在減麼下移除溶劑以得到呈黃色固體狀之腈 1-F。MS (ESI+)=361.3 (M+l); ’H NMR (500 MHz, CDC13): δ 130071.doc -46- 200901987 2.15 (6H,m),2.22 (6H,m), 3.47 (3H,s),7·51 (1H,m),7·72 (2H,m), 7·87 (1H,m) ppm。 步驟F : 將腈1-F(0.56 g,1.6 mmol)及經基胺(50%水溶液,4 ml) 於乙醇(40 ml)中之溶液在80°C下加熱1 8 h。將所得混合物 冷卻至室溫且真空濃縮。將固體懸浮於甲苯中,在真空中 移除溶劑’且將固體(1-G)在減壓下乾燥,且不經進一步 純化用於下一步驟中。MS (ESI+)=394.3 (M+1)。 步驟G : 將 HATU(2.93 g,7.63 mmol)添加至 2,2-二氟丙酸(0.84 g, 7.63 mmol)及N,-羥基-4-{4-甲基-5-[2-(三氟甲基)苯基]-4H-1,2,4-三唑-3-基}雙環[2.2.2]辛烷-1-羰醯亞胺醯胺(1_(3)(1.〇 g,2.54 mmol)於無水DMF(30 ml)中之溶液中,接著添加 DIEA(2.2 ml,12.7 mmol)。將所得混合物在室溫下攪拌48 小時’接著加熱至110。〇歷時3小時。在冷卻至室溫後,在 減壓下移除溶劑。將殘餘物溶解於乙酸乙酯中,用水、飽 和碳酸氫鈉溶液及鹽水洗滌。藉由管柱層析使用1〇〇0/〇乙 酸乙酯作為溶離劑來純化粗產物以產生呈白色粉末狀之^ H ° MS (ESI + )=468.3 (M+l); 'H NMR (500 MHz, CDC13): δ 2.10-2.34 (15H, m),3.57 (3H,s),7.73-7.75 (3H, m),7.86 130071.doc -47- 200901987
實例2
5-(3,3-二氟環丁基)-3-(4-{4-甲基_5_【2·(三氟甲基)苯基卜 AH、1,2,4-三唑 _3_基}雙環[2.2.2】辛 _1_基)-:1,2,4-噁二唑(2_Ε)
EtOH-CH2CI2
DAST
OBn 2-C
0 γ^Α〇η (1) CsC03, EtOH (2) BnBr, CH3CN
2·Β (1) GDI, CH2CI2
d-G)
步驟A : 將3側乳基環丁烧甲酸(2-A)(1.0 g, 10.0 mmol)溶解於無 水乙醇(25 ml)中,且添加碳酸铯(1.66 g, 5.1 mmol)。在室 溫下在氮下攪拌4小時後,將反應混合物濃縮。將殘餘物 再溶解於無水乙腈(5〇 ml)中且用苯曱溴(1_2 ml, 1〇.〇 ml)處 理。將混合物在室溫下在氮氣氛下攪拌12小時。接著在減 壓下移除溶劑且使殘餘物在乙酸乙酯與水之間分溶。使用 石夕膠層析用1 〇〇%己烷至96〇/。己烷/乙酸乙酯之梯度溶離來 130071.doc -48- 200901987 純化粗產物以得到 2-B。NMR (500 MHz,CDC13): δ 3.30-3.48 (5H,m),5.22 (2H,s),7.37-7.41 (5H,m) ppm。 步驟B : 將3-側氧基烷丁烷甲酸苯甲酯(2-B)(l.23 g,6.03 mmol) 溶解於二氣甲烷(35 ml)中。在氮下添加DAST(8.0 ml,6.03 mmol),p遺後添加無水乙醇(0·4以,7.23 mmol)。將混合物 -攪拌12小時,之後將其用二氯甲烷稀釋,相繼用飽和碳酸 氫鈉溶液、1 N鹽酸水溶液及鹽水洗滌。將有機層經由無 〇 水硫酸鈉乾燥,過濾且濃縮。藉由矽膠層析用93%己烷/乙 酸乙酯作為溶離劑來純化粗產物以得到呈油狀之2-C。 NMR (500 MHz, CDC13): δ 2.81- 2.93 (4Η, m), 3.01- 3.04 (1Η, m), 5.2 0 (2 Η,s),7.3 6 - 7 4 2 (5 Η, m ) ρ ρ m。 步驟C : 將3,3->一氣環丁烧甲酸本甲醋(2-C)(0.84 g,3.72 mmol)溶 解於乙醇(40 ml)中,且添加約20 mg鈀/活性碳。將混合物 在室溫下在氫氣氛下攪拌12小時,且接著經由矽藻土墊過 (’ 濾。將濾液濃縮且在真空中乾燥以得到2-D。丨11 NMR (500 MHz, CDC13): δ 2.86-2.93 (4Η, m), 3.02-3.04 (1H, m) ppm。 步驟D : 將Ν’-羥基-4-{4 -甲基- 5-[2-(三氟甲基)苯基]-化“又‘三 唑-3 -基}雙環[2.2.2]辛烷-1-羰醯亞胺醯胺2〇 mg, 0.305 mmol)添加至經預攪拌之3,3-二氟環丁烷甲酸2_ D(166 mg,1.22 mmol)及碳基二咪唑(198 mg,1.22 mmol)於 130071.doc -49- 200901987 CH2C12(8 ml)中之溶液中。將所得混合物在室溫下攪拌48 h ’接著濃縮。將固體再懸浮於甲苯中且在氮氣氛下回流3 h。藉由C-18逆相HPLC用30-80%乙腈/水(含0.1% TFA)溶 離來純化產物以得到呈白色粉末狀之2-E。MS (ESI+)=494.2 (M+l); ]H NMR (500 MHz, CDC13): δ 2.09 (6H, m), 2.31 (6H, m), 3.03-3.11 (4H, m), 3.57-3.61 (4H, m),7.56 (1H,m),7.71 (2H, m), 7.86 (1H,m) ppm。Shh-發光 II檢定:IC5〇 : 1.4 μΜ。 實例3
5-(1-氟-1-甲基乙基-3-(4-{4_甲基-5-[2-(三氟甲基)苯基卜 411-1,2,4-三唑-3-基}雙環[2.2.2】辛_1-基)-1,2,4-噁二唑(3-八)
h2n n~f (1-G) (3) 100° C, 1.5 hr 將2-曱基-2-氟丙酸(108 mg,1.02 mmol)及Γ,1碳基二口米 唑(144 mg, 0.888 mmol)於無水DMF(2.5 ml)中之溶液在室 溫下在氮氣氛下搜拌30 min。向其中添加Ν'-經基-4-{4-甲 基_5-[2-(三氟甲基)苯基]-4H-1,2,4-三唑_3_基}雙環[2.2.2] 辛烧-1-羧醯亞胺醯胺(1-G)(139.5 mg,0.355 mmol)且將溶液 130071.doc -50- 200901987 在N2下擾掉隔夜。將反應物在加熱塊中在100°C下加熱1.5 小時。在真空中移除DMF且將固體再溶解於ch3CN(4如) 中。藉由C-18逆相層析用1〇_9〇% CH3cN(〇 1% TFA)/水 (〇_1% TFA)溶離來純化產物。移除溶劑且將殘餘物溶解於 DCM中且自飽和碳酸氫鈉水溶液分離游離驗。將有機層經
MgS〇4乾燥且過濾。將溶劑用CH3CN/水替換且凍乾以得到 呈白色固體狀之5-(1·氟-1_甲基乙基)_3_(4_{4_甲基巧_[2 (二氟甲基)苯基]_4H-1,2,4-三唑-3-基}雙環[2.2.2]辛美) i,2,4U坐(3-A)。MS (ESI>464.13 (Μ+1)】η ⑽ MHz, CDC13): δ 7.89-7.85 (m, 1 H), 7.75-7.69 (m 2 H) 7.55 (t,1H),3.52 (s,3 H),2.30 (dd,6 H) 2 (dd, 6 H), 1-90 (s,3 H),1.86 (s,3 H)。Shh-發光 π檢定.Tri . \ .比5〇 : 4.2 μΜ。
實例4 F
2-(1,1-二 n 6 基)-5-(4-(4-甲基·5_[2_(三氟 f 基)苯基】 1,2,4-三嗤-3-基}雙環[2.2.2】辛小基二唑⑷b)
1-D 13007l.doc 200901987
ch3cf2cooh v_7 ch2ci2 步驟A : 將酸 1-D(1.0 g,2.64 mmol)溶解於 DMF(30 ml)中,且添 加TFFH(0.84 g,3.18 mmol),隨後添加三乙胺(0.88 ml, 6.34 mmol)及無水肼(0.12 ml,3.95 mmol)。在室溫下在氮 下攪拌混合物12小時。接著將混合物在減壓下濃縮以移除 DMF。將殘餘物溶解於乙酸乙酯中且用飽和碳酸氫鈉溶液 及鹽水洗滌。將有機層經由無水硫酸鈉乾燥,過濾且濃 縮。將產物(4-{4-曱基-5-[2-(三氟甲基)苯基]-4H-1,2,4-三 唑-3-基}雙環[2.2.2]辛烷-1-卡脲,4-八)藉由與甲苯共蒸發 數次來進一步乾燥,之後用於下一步驟中。MS (ESI+)= 394.2 (M+1)。 步驟B : 將4-{4-曱基-5-[2-(三氟甲基)苯基]-4H-1,2,4-三唑-3-基} 雙環[2_2.2]辛烧-1-卡腺(4-八)(334 111叾,0.85〇111111〇1)與2,2-二 氟丙酸(78 mg,0.708 mmol)之混合物懸浮於二氯甲烷中, 且添加固體形式之DMC( 1.2 g,7.08 mmol)。將混合物在室 溫下在氮下攪拌48小時,之後將其用二氯曱烷稀釋,用 水、飽和碳酸氫納溶液及鹽水洗蘇。藉由管柱層析來純化 粗產物以得到呈白色固體狀之4-B。MS (ESI+)=468.3 (M+1); ]H NMR (500 MHz, CDC13): δ 2.15-2.33 (15H, m), 130071.doc •52- 200901987 3.52 (3H,s),7.61 (1H,m),7.72 (2H, m),7.85 (1H, m) ppm。Shh-發光 II檢定:IC5〇 : 9.3 μΜ。 實例5
2-(3,3-二氟環丁基)_5·(4-{4-甲基-S-[2-(三氟甲基)苯基】 41^,2,4-三嗅-3-基}雙環【2.2.2】辛小基3
f 步驟A :
自酸肼4-A(119 mg,0.303 mmol)及3,3_二氟環丁院甲酸 (49.4 mg,0.363 mmol)使用實例4’步驟B中所述之方法來 製備三唑5-A。在藉由C-18逆相HPLC(使用20-8〇〇/。及25-50%乙腈/水(分別含0.1% TFA)溶離)純化兩次之後分離得 呈白色粉末狀之2-(3,3-二氟環丁基)-5-(4-{4-甲基_5_[2_(三 氟曱基)苯基]-4H-1,2,4-三唑-3-基}雙環[2.2.2]辛-l_基)_ 1,3,4-噁二唑(5-A)。MS (ESI+)=494.2 (M+l)。Shh-發光 π 檢定:IC50 : 2 μΜ。 130071.doc -53- 200901987 實例6
N一 N CF3 2-(1-氟-1_甲基乙基)-5-(4-{4-甲基_5_丨2_(三氟甲基)苯基卜 4H-l,2,4-三唑-3-基}雙環[2.2·2】辛-l_基)_l,3,4-噁二唑(6-B)
步驟A : 將2-甲基-2-氟丙酸(70 mg,0.66 mmol)及1,,Γ-碳基二咪 唑(107 mg,0.66 mmol)於無水DMF(2 ml)中之溶液在室溫 下在氮氣氛下攪拌30 min。向此溶液中添加醯肼4-a(200 mg,0.5 09 mmol)且將溶液在N2下攪拌隔夜。在真空中移除 DMF且將固體再溶解於含少許DMSO之CH3CN(4 ml)中。 藉由 C-18 逆相層析用 10-90% CH3CN(0.1% TFA)/水(0.1% TFA)溶離來純化產物。在真空中移除溶劑且自DCM及飽 和碳酸氫鈉水溶液分離游離鹼產物。將有機層經MgS04乾 燥且過濾。移除溶劑以得到產物6-A。MS (ESI+)=482.30 I30071.doc -54- 200901987 (M+l) 〇 步驟B : 向步驟A中獲得之物質中添加甲苯(3 mL)及亞硫醯氣(2 叫,且裝配回流冷凝器,將溶液在氮下加熱至饥。H、 時後在減壓下移除溶劑且將殘餘物溶解於甲苯中,在減壓 下移除甲苯。將殘餘物溶解SCH3CN(4⑺丨)中且藉由c_18 逆相層析用 10-90% CH3CN(0,1% TFA)/水(0.1% TFA)溶離 來純化產物。在真空中移除溶劑且自DCM及飽和碳酸氫鈉 、 水溶液分離游離鹼產物。將有機層用鹽水洗滌且經MgS04 乾燥且過濾。移除溶劑且自ch3cn及水凍乾產物以得到呈 白色固體狀之2-(1-氟-1-曱基乙基)-5-(4-{4-曱基-5-[2-(三 氟曱基)苯基]-4H-1,2,4-三唑-3-基}雙環[2.2.2]辛-1-基)-l,3,4-噁二唑(6_B)。MS(ESΓ)=463.98 (M+);1HNMR(500 MHz, CDC13): δ 7.89-7.85 (m, 1H), 7.76-7.70 (m, 2H), 7.58 (s, 1H), 3.53 (s, 3H), 2.32 (dd, 6H), 2.20 (dd, 6H), 1.92 (s, 3H),1.87 (s,3H)。 130071.doc 55-
Claims (1)
- 200901987 十、申請專利範圍: 1.—種以下式I之化合物或其醫藥學可接受之鹽或溶劑合物 於製造治療或預防可由Smo拮抗作用改善之病狀之藥劑 上之用途, 、X/ Y及Z中之兩者表示氮原子,且另一者表示氧原子; R及R與其所連原子一起表示視情況經i _2個氟原子取代 之環丁基環,且R3表示氫或氟原子; 或 r1表示甲基; R表示甲基或氟原子;且 r3表示氟原子。 2.如請求項 Z為N。 之用途,其中X及γ之 —為Ο且另一者為N, 且 如明求項1之用途,其中該化合物具有結構式^ R1r2r3c130071.doc 200901987 4H-1 2 4既乙基)3 (4 {4_甲基'Η2·(三氟甲基)苯基]· 5们,—冰3.基则[2.2.2]辛小基心 P’·3--氟環丁基)-3-(4-{4-甲美 ς r 4H 1 ο ^ 土 _5吖2~(三氟甲基)苯基]_ -I,2,4-三唑_3_基}雙環[2 2 5_〇.^ , 』〒 K基)-1,2,4-噁二唑; (氟-1-甲基乙基)·3-(4-{4-甲甚ς r 4H-1 2 a _ 基·5~[2-(三氟甲基)苯基l· ’2,4-三唑_3_基}雙環[2 2 2-ri 1 - ^ !·基)-1,2,4-噁二唑; ,一軋乙基)-5-(4-(4-甲基_5,丨7 4H-1 2 d [2·(三氟甲基)苯基l· H】,2,‘三唑-3-基}雙環 X 2-(3 3 - 基)-1,3,4-噁二吐, H·3-—鼠環丁基)-5-(4-{4-甲 Λ $ 4H-1 2 4-^ . 土_5_[2_(三氟甲基)苯基]- ,,4-二唑_3_基}雙環[2 2 2]辛 2-(l-i 1 m «. 基)-l,3,4-噁二唑; -甲基乙基)-5-(4-{4-甲美ς F 4H-1 2 4-^ 土 '5,[2_(三氟甲基)苯基]- ,2,4-二唑_3_基}雙環[2 2 2]辛 或其醫筚風卜了拉戈 基)-1,3,4-噁二唑; 上菌樂予上可接受之鹽或溶劑合物。 5’々明求項1之用途,其_該化合物為: Η1,1·二氟乙基)-3_(4_{4甲基 _ * 4Η-1 2 4 - (二氣甲基)苯基]- ,2,4-二唑 _3_基}雙環[2 2 2]辛 或其醫鎗風, 基)·1,2,4-噁二唑; 醫樂予上可接受之鹽或溶劑合物。 6 ·如凊求項1 $田、全 ^ , 貝1之用途,其中該化合物為: 5_(3’3'二就環丁基)_3·(4-{4_ 甲基- 4Η- 1,24 — I (—鼠甲基)苯基]- ,-二唑-3-基}雙環ρ 2 2]辛 或其醫筚風^ 〒1-基)_〗,2,4-噁二唑; 7·如請求箱,— 物。 項1之用途,其中該化合物 ,3_基}雙卯·2·2]辛小基 13007I.doc 200901987 或其醫藥學上可接受之鹽或溶劑合物。 8. 如請求項1之用途’其中該化合物為: 2-(1小二氟乙基)_5_(4_{4_曱基_ 4Η·1,2,4-:唑 3 L (―軋甲基)苯基]- ,,—坐_3_基}雙環[2.22]辛小基)十3木。亞 或其醫藥學上可接受之鹽或溶劑合物。 一坐, 9. 如凊求項1至8中任一馆夕田、全 一&+ 項之用途’其中該病狀為癌症。 10. 如晴求項9之用途,其中 £症 苒^ k目暴細胞癌、神經 二:胞瘤、前列腺癌、胰腺癌、乳癌、結腸癌、小細 ::、肉瘤、淋巴瘤、白血病、胃腸癌、多發性骨髓 、神經膠質瘤、肝細胞癌、偶發性及家族性基細胞 癌、偶發性神經管胚細胞瘤、腦膜瘤、乳癌、食道鱗狀 細胞癌及膀胱癌。 U. 一種如請求項1至8中任-項之化合物或其醫藥學上可接 受之鹽或溶劑合物之用途,其係用於製造癌症治療之化 學或放射致敏劑。 12.種用於冶療或預防癌症之醫藥組合物,其包含如請求 項至8中任項之化合物或其醫藥學上可接受之鹽或溶 劑合物。 13. —種用於治療或預防癌症之醫藥組合,其包含供同時、 單獨或相繼投藥之如請求項1至8中任一項之化合物或其 醫藥學上可接受之鹽或溶劑合物及抗癌劑。 14. 一種如請求項1至8中任一項之化合物或其醫藥學上可接 受之鹽或溶劑合物之用途,其係用於製造治療或預防可 由Smo拮抗作用改善之病狀之藥劑。 130071.doc 200901987 七、指定代表圖: (一) 本案指定代表圖為:(無) (二) 本代表圖之元件符號簡單說明: 八、本案若有化學式時,請揭示最能顯示發明特徵的化學式:130071.doc
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92501807P | 2007-04-18 | 2007-04-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200901987A true TW200901987A (en) | 2009-01-16 |
Family
ID=39433852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW097113665A TW200901987A (en) | 2007-04-18 | 2008-04-15 | Triazole derivatives which are Smo antagonists |
Country Status (12)
Country | Link |
---|---|
US (1) | US7691887B2 (zh) |
EP (1) | EP2136803B1 (zh) |
JP (1) | JP5498936B2 (zh) |
CN (1) | CN101663033B (zh) |
AR (1) | AR066063A1 (zh) |
AT (1) | ATE555785T1 (zh) |
AU (1) | AU2008241527B2 (zh) |
CA (1) | CA2683946C (zh) |
CL (1) | CL2008001074A1 (zh) |
PE (1) | PE20090806A1 (zh) |
TW (1) | TW200901987A (zh) |
WO (1) | WO2008130552A1 (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI433674B (zh) | 2006-12-28 | 2014-04-11 | Infinity Discovery Inc | 環杷明(cyclopamine)類似物類 |
KR20100137416A (ko) * | 2007-12-27 | 2010-12-30 | 인피니티 파마슈티칼스, 인코포레이티드 | 암 치료법 |
CN101917853B (zh) | 2007-12-27 | 2014-03-19 | 无限药品股份有限公司 | 立体选择性还原的方法 |
US20100297118A1 (en) * | 2007-12-27 | 2010-11-25 | Macdougall John | Therapeutic Cancer Treatments |
GB0813740D0 (en) * | 2008-07-28 | 2008-09-03 | Angeletti P Ist Richerche Biologica | Therapeutic compounds |
EP2334683B1 (en) * | 2008-08-29 | 2017-03-22 | MSD Italia S.r.l. | Saturated bicyclic heterocyclic derivatives as smo antagonists |
CA2769795C (en) | 2009-08-05 | 2020-01-07 | Infinity Pharmaceuticals, Inc. | Enzymatic transamination of cyclopamine analogs |
WO2011063309A1 (en) * | 2009-11-20 | 2011-05-26 | Infinity Pharmaceuticals, Inc. | Methods and compositions for treating hedgehog-associated cancers |
US9376447B2 (en) | 2010-09-14 | 2016-06-28 | Infinity Pharmaceuticals, Inc. | Transfer hydrogenation of cyclopamine analogs |
KR20160061911A (ko) | 2013-04-08 | 2016-06-01 | 데니스 엠. 브라운 | 최적하 투여된 화학 화합물의 치료 효과 |
CN104324039A (zh) * | 2014-10-20 | 2015-02-04 | 付茜 | 一种治疗人身体表面脂肪瘤的药剂及使用方法 |
AU2016271468B2 (en) | 2015-06-04 | 2020-01-02 | Sol-Gel Technologies Ltd. | Topical formulations for delivery of hedgehog inhibitor compounds and use thereof |
CN108623446A (zh) * | 2017-03-24 | 2018-10-09 | 北京艾德旺科技发展有限公司 | 一种合成3,3-二氟环丁烷甲酸的方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7291626B1 (en) | 1998-04-09 | 2007-11-06 | John Hopkins University School Of Medicine | Inhibitors of hedgehog signaling pathways, compositions and uses related thereto |
JP4368683B2 (ja) | 2002-02-01 | 2009-11-18 | メルク エンド カムパニー インコーポレーテッド | 糖尿病、肥満症および脂質代謝異常の治療に有用な11−ベータ−ヒドロキシステロイドデヒドロゲナーゼ1阻害剤 |
JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
JP4499106B2 (ja) | 2003-05-29 | 2010-07-07 | メルク・シャープ・エンド・ドーム・コーポレイション | 11−ベータ−水酸化ステロイド脱水素酵素−1の阻害剤としてのトリアゾール誘導体 |
US8067608B2 (en) | 2003-09-29 | 2011-11-29 | The Johns Hopkins University | Hedgehog pathway antagonists |
CN101018783B (zh) | 2004-04-30 | 2012-11-21 | 遗传技术研究公司 | Hedgehog信号传导途径的喹喔啉抑制剂 |
ATE472531T1 (de) | 2004-08-06 | 2010-07-15 | Merck Sharp & Dohme | Sulfonylverbindungen als hemmer von 11-beta- hydroxysteroiddehydrogenase-1 |
BRPI0514444A (pt) | 2004-08-27 | 2008-06-10 | Infinity Pharmaceuticals Inc | análogos de ciclopamina e métodos de uso destes |
CN102964294A (zh) | 2004-09-02 | 2013-03-13 | 遗传技术研究公司 | Hedgehog信号转导的吡啶基抑制剂 |
KR20070083836A (ko) | 2004-10-28 | 2007-08-24 | 아이알엠 엘엘씨 | 헷지혹 경로 조절제로서의 화합물 및 조성물 |
NZ555419A (en) | 2004-11-03 | 2009-07-31 | Curis Inc | Mediators of the hedgehog gene signaling pathways, compositions and uses related thereto |
EP1940393B1 (en) * | 2005-10-20 | 2012-07-25 | Merck Sharp & Dohme Corp. | Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
-
2008
- 2008-04-15 CL CL2008001074A patent/CL2008001074A1/es unknown
- 2008-04-15 CN CN2008800127274A patent/CN101663033B/zh active Active
- 2008-04-15 TW TW097113665A patent/TW200901987A/zh unknown
- 2008-04-15 US US12/082,933 patent/US7691887B2/en active Active
- 2008-04-15 JP JP2010504069A patent/JP5498936B2/ja active Active
- 2008-04-15 AR ARP080101540A patent/AR066063A1/es unknown
- 2008-04-15 EP EP08742913A patent/EP2136803B1/en active Active
- 2008-04-15 AT AT08742913T patent/ATE555785T1/de active
- 2008-04-15 WO PCT/US2008/004862 patent/WO2008130552A1/en active Application Filing
- 2008-04-15 PE PE2008000654A patent/PE20090806A1/es not_active Application Discontinuation
- 2008-04-15 CA CA2683946A patent/CA2683946C/en active Active
- 2008-04-15 AU AU2008241527A patent/AU2008241527B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2683946C (en) | 2013-01-22 |
WO2008130552A1 (en) | 2008-10-30 |
US7691887B2 (en) | 2010-04-06 |
JP2010524937A (ja) | 2010-07-22 |
AU2008241527A1 (en) | 2008-10-30 |
ATE555785T1 (de) | 2012-05-15 |
CL2008001074A1 (es) | 2009-06-05 |
EP2136803A1 (en) | 2009-12-30 |
CA2683946A1 (en) | 2008-10-30 |
EP2136803B1 (en) | 2012-05-02 |
US20080262051A1 (en) | 2008-10-23 |
CN101663033A (zh) | 2010-03-03 |
PE20090806A1 (es) | 2009-06-27 |
JP5498936B2 (ja) | 2014-05-21 |
AR066063A1 (es) | 2009-07-22 |
CN101663033B (zh) | 2013-01-16 |
AU2008241527B2 (en) | 2014-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200901987A (en) | Triazole derivatives which are Smo antagonists | |
US11931363B2 (en) | Triazolopyrimidine compounds and uses thereof | |
ES2660914T3 (es) | Derivados de 6-(5-hidroxi-1H-pirazol-1-il)nicotinamida y su uso como inhibidores de PHD | |
BR112019026478A2 (pt) | compostos para modulação da atividade de s1p1 e métodos de uso dos mesmos | |
TW201002683A (en) | Novel substituted pyridin-2-ones and pyridazin-3-ones | |
TW200908983A (en) | Heterocyclic compounds and uses thereof | |
US20110183974A1 (en) | 1,2,4-oxadiazole substituted piperidine and piperazine derivatives as smo antagonists | |
TW201200522A (en) | Analogues for the treatment or prevention of flavivirus infections | |
TR201806882T4 (tr) | Selektif östrojen reseptörü yıkıcıları olarak benzotiofen türevleri ve bunların bileşimleri. | |
CA2889756C (en) | Thiohydantoin compounds as androgen receptor modulators | |
JP2000510870A (ja) | Npy5受容体アンタゴニストとしてのアミド類 | |
TW200829584A (en) | Thiazole and oxazole-substituted arylamides | |
KR20210038911A (ko) | Smarca2 길항제로서 유용한 피리딘-2-온 화합물 | |
KR20170082532A (ko) | 운동실조 모세혈관확장증 및 Rad3-관련 (ATR) 단백질 키나제 억제제 | |
TW200938548A (en) | Anti-viral compounds, compositions, and methods of use | |
CN102822169A (zh) | 取代的萘基-嘧啶化合物 | |
WO2019158070A1 (zh) | A2a和/或a2b受体拮抗剂 | |
WO2023125707A1 (zh) | 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途 | |
WO2010082044A1 (en) | Unsaturated bicyclic heterocyclic derivatives as smo antagonists | |
US20130053396A1 (en) | Piperidine and piperazine derivatives as smo antagonists |